0,BRAF:AKAP9-BRAF,[Variant]
1,BRCA1:MUTATION,[Variant]
2,Epithelial Ovarian Cancer,[Disease]
3,BRCA2:MUTATION,[Variant]
4,CCNE1:AMPLIFICATION,[Variant]
5,T-cell Acute Lymphoblastic Leukemia,[Disease]
6,EGFR:AMPLIFICATION,[Variant]
7,Barrett's Adenocarcinoma,[Disease]
8,Cervical Squamous Cell Carcinoma,[Disease]
9,EGFR:COPY NUMBER VARIATION,[Variant]
10,EGFR:OVEREXPRESSION,[Variant]
11,Brain Glioblastoma Multiforme,[Disease]
12,ERG,[Gene]
13,ERG:EWSR1-ERG,[Variant]
14,ERG:TMPRSS2-ERG,[Variant]
15,FGFR3:Y375C,[Variant]
16,FLI1:EWSR1-FLI1,[Variant]
17,FOXL2,[Gene]
18,FOXL2:C134W,[Variant]
19,Ovarian Granulosa Cell Tumor,[Disease]
20,IDH2:R172,[Variant]
21,IKZF1,[Gene]
22,IKZF1:DELETION,[Variant]
23,B-lymphoblastic Leukemia/lymphoma,[Disease]
24,KIT:M541L,[Variant]
25,KIT:V560DEL,[Variant]
26,Thymic Carcinoma,[Disease]
27,KRAS:G13,[Variant]
28,KRAS:Q61,[Variant]
29,Oligodendroglioma,[Disease]
30,NCOA3,[Gene]
31,NCOA3:AMPLIFICATION,[Variant]
32,NCOA3:OVEREXPRESSION,[Variant]
33,NOTCH1:MUTATION,[Variant]
34,NOTCH1:P2514FS,[Variant]
35,Thyroid Gland Follicular Carcinoma,[Disease]
36,PAX8,[Gene]
37,PAX8:PAX8-PPARG,[Variant]
38,Renal Cell Carcinoma,[Disease]
39,PGR,[Gene]
40,PGR:EXPRESSION,[Variant]
41,Tamoxifen,[Drug]
42,"Exemestane,Tamoxifen",[Drug]
43,PIK3CA:AMPLIFICATION,[Variant]
44,Gastric Adenocarcinoma,[Disease]
45,PTEN:DELETION,[Variant]
46,Prostate Adenocarcinoma,[Disease]
47,PTEN:LOSS,[Variant]
48,Temsirolimus,[Drug]
49,SMAD4,[Gene]
50,SMAD4:MUTATION,[Variant]
51,Pancreatic Adenocarcinoma,[Disease]
52,SMARCA4,[Gene]
53,SMARCA4:MUTATION,[Variant]
54,Small-cell Carcinoma Of The Ovary Of Hypercalcemic Type,[Disease]
55,SMARCA4:INACTIVATING MUTATION,[Variant]
56,TERT,[Gene]
57,TERT:AMPLIFICATION,[Variant]
58,Acral Lentiginous Melanoma,[Disease]
59,TERT:PROMOTER MUTATION,[Variant]
60,Skin Melanoma,[Disease]
61,TP53:DELETERIOUS MUTATION,[Variant]
62,TP53:MUTATION,[Variant]
63,Esophagus Squamous Cell Carcinoma,[Disease]
64,Myeloid Neoplasm,[Disease]
65,TP53:TRUNCATING MUTATION,[Variant]
66,TTF1,[Gene]
67,TTF1:AMPLIFICATION,[Variant]
68,ERBB2:AMPLIFICATION,[Variant]
69,Her2-receptor Positive Breast Cancer,[Disease]
70,Trastuzumab,[Drug]
71,CHEK2,[Gene]
72,CHEK2:LOSS-OF-FUNCTION,[Variant]
73,"Gemcitabine,Trametinib",[Drug]
74,CDK12,[Gene]
75,CDK12:LOSS-OF-FUNCTION,[Variant]
76,Ovarian Serous Carcinoma,[Disease]
77,Peripheral T-cell Lymphoma,[Disease]
78,NT5C2,[Gene]
79,NT5C2:R367Q,[Variant]
80,"Mercaptopurine,Thioguanine",[Drug]
81,NT5C2:K359Q,[Variant]
82,NT5C2:D407A,[Variant]
83,"Nelarabine,Arabinosylguanine",[Drug]
84,ABL1:BCR-ABL F317L,[Variant]
85,TP53:DNA BINDING DOMAIN MUTATION,[Variant]
86,Oral Squamous Cell Carcinoma,[Disease]
87,"Multikinase Inhibitor AEE788,Gefitinib",[Drug]
88,Rociletinib,[Drug]
89,ATM:S2289*,[Variant]
90,ATM:N2875H,[Variant]
91,NF2,[Gene]
92,NF2:Y177FS,[Variant]
93,Peritoneal Mesothelioma,[Disease]
94,"Cisplatin,Carboplatin",[Drug]
95,PDGFRA:V561A,[Variant]
96,TERT:C228T,[Variant]
97,XRCC1,[Gene]
98,XRCC1:R194W,[Variant]
99,"Gemcitabine,Vinorelbine,Docetaxel",[Drug]
100,GSTP1,[Gene]
101,GSTP1:DELETION,[Variant]
102,"Cisplatin,Carboplatin,Paclitaxel",[Drug]
103,BIRC7,[Gene]
104,BIRC7:AMPLIFICATION,[Variant]
105,Colon Cancer,[Disease]
106,Cisplatin,[Drug]
107,EGFR:EXON 4 DELETION,[Variant]
108,KRAS:RS61764370,[Variant]
109,"Carboplatin,Paclitaxel",[Drug]
110,ERCC5,[Gene]
111,ERCC5:RS751402,[Variant]
112,Parietal Lobe Ependymoma,[Disease]
113,KIT:3' UTR MUTATION,[Variant]
114,EZH2:INTRON 6 MUTATION,[Variant]
115,MTHFR,[Gene]
116,MTHFR:A222V,[Variant]
117,Fluorouracil,[Drug]
118,GSTP1:I105V,[Variant]
119,FOLFOX Regimen,[Drug]
120,ABCG2,[Gene]
121,ABCG2:Q141K,[Variant]
122,XRCC1:Q399R,[Variant]
123,Cervical Cancer,[Disease]
124,"Carboplatin,Cisplatin",[Drug]
125,ABCB1,[Gene]
126,ABCB1:S893T,[Variant]
127,ABCB1:I1145I,[Variant]
128,ERCC2,[Gene]
129,ERCC2:K751Q,[Variant]
130,Osteosarcoma,[Disease]
131,TYMS,[Gene]
132,TYMS:5' TANDEM REPEAT,[Variant]
133,"Fluorouracil,Irinotecan",[Drug]
134,LRP1B,[Gene]
135,LRP1B:EXON 12-22 DELETION,[Variant]
136,FGFR1,[Gene]
137,FGFR1:AMPLIFICATION,[Variant]
138,Lung Squamous Cell Carcinoma,[Disease]
139,FGFR1:EXPRESSION,[Variant]
140,ROS1,[Gene]
141,ROS1:REARRANGEMENT,[Variant]
142,MET,[Gene]
143,MET:AMPLIFICATION,[Variant]
144,Onartuzumab,[Drug]
145,ATR,[Gene]
146,ATR:I774FS,[Variant]
147,Endometrial Cancer,[Disease]
148,"Fluorouracil,Platinum Compound,Cetuximab",[Drug]
149,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,[Drug]
150,CDKN2A:p16 EXPRESSION,[Variant]
151,RET:KIF5B-RET,[Variant]
152,Vandetanib,[Drug]
153,HRAS,[Gene]
154,HRAS:G13D,[Variant]
155,HRAS:MUTATION,[Variant]
156,"Binimetinib,MTOR Kinase Inhibitor AZD8055,Selumetinib,Everolimus,MEK Inhibitor PD0325901",[Drug]
157,CD274,[Gene]
158,CD274:EXPRESSION,[Variant]
159,"Nivolumab,Pembrolizumab",[Drug]
160,MTOR,[Gene]
161,MTOR:MUTATION,[Variant]
162,"Pazopanib,Everolimus",[Drug]
163,AKT2,[Gene]
164,AKT2:EXPRESSION,[Variant]
165,Uprosertib,[Drug]
166,Capivasertib,[Drug]
167,"Pictilisib,Akt Inhibitor MK2206",[Drug]
168,PI3Kbeta Inhibitor AZD8186,[Drug]
169,MTOR:H1968Y,[Variant]
170,"PI3K/BET Inhibitor LY294002,Capivasertib",[Drug]
171,"Buparlisib,Carboplatin,Paclitaxel",[Drug]
172,NF2:K159FS*16,[Variant]
173,EGFR:S492R,[Variant]
174,FBXW7,[Gene]
175,FBXW7:MUTATION,[Variant]
176,SMAD4:UNDEREXPRESSION,[Variant]
177,MTOR:P2213S,[Variant]
178,BRAF:AGK-BRAF,[Variant]
179,BRAF:PAPSS1-BRAF,[Variant]
180,BRAF:TRIM24-BRAF,[Variant]
181,BRAF:L597R,[Variant]
182,ERBB3,[Gene]
183,ERBB3:OVEREXPRESSION,[Variant]
184,NT5E,[Gene]
185,NT5E:OVEREXPRESSION,[Variant]
186,EZH2:OVEREXPRESSION,[Variant]
187,GSK321,[Drug]
188,MYD88,[Gene]
189,MYD88:OVEREXPRESSION,[Variant]
190,MET:EXON 14 SKIPPING MUTATION,[Variant]
191,PIK3CA:P471L,[Variant]
192,Merkel Cell Carcinoma,[Disease]
193,Idelalisib,[Drug]
194,RET:EXPRESSION,[Variant]
195,RIT1,[Gene]
196,RIT1:OVEREXPRESSION,[Variant]
197,RIT1:MUTATION,[Variant]
198,"Pictilisib,Selumetinib",[Drug]
199,MYCN,[Gene]
200,MYCN:AMPLIFICATION,[Variant]
201,FACT Complex-targeting Curaxin CBL0137,[Drug]
202,SMO,[Gene]
203,SMO:D473H,[Variant]
204,Medulloblastoma,[Disease]
205,Vismodegib,[Drug]
206,SMO:MUTATION,[Variant]
207,Basal Cell Carcinoma,[Disease]
208,"PSI,Arsenic Trioxide",[Drug]
209,PTCH1,[Gene]
210,PTCH1:MUTATION,[Variant]
211,Sonidegib,[Drug]
212,PTCH1:LOH,[Variant]
213,STK11,[Gene]
214,STK11:EXON 1-2 MUTATION,[Variant]
215,STK11:UNDEREXPRESSION,[Variant]
216,SB202190,[Drug]
217,SYK,[Gene]
218,SYK:OVEREXPRESSION,[Variant]
219,Pictilisib,[Drug]
220,Oropharynx Cancer,[Disease]
221,AKTi-1/2,[Drug]
222,ALK:EML4-ALK L1152R,[Variant]
223,ALK:EML4-ALK G1269A,[Variant]
224,ERBB4,[Gene]
225,ERBB4:MUTATION,[Variant]
226,PIK3CA:MUTATION,[Variant]
227,Cabozantinib,[Drug]
228,EGFR:VIII,[Variant]
229,Afatinib,[Drug]
230,PTEN:EXPRESSION,[Variant]
231,NRG1,[Gene]
232,NRG1:EXPRESSION,[Variant]
233,Seribantumab,[Drug]
234,"Cisplatin,Gemcitabine,Carboplatin,Paclitaxel",[Drug]
235,AREG,[Gene]
236,AREG:EXPRESSION,[Variant]
237,Nimotuzumab,[Drug]
238,TGFA,[Gene]
239,TGFA:EXPRESSION,[Variant]
240,EGFR:G724S,[Variant]
241,EREG,[Gene]
242,EREG:EXPRESSION,[Variant]
243,MAPK1,[Gene]
244,MAPK1:E322K,[Variant]
245,MAPK1:AMPLIFICATION,[Variant]
246,WZ4002,[Drug]
247,KRAS:A146V,[Variant]
248,Abemaciclib,[Drug]
249,MET:MUTATION,[Variant]
250,Papillary Renal Cell Carcinoma,[Disease]
251,Foretinib,[Drug]
252,Infigratinib,[Drug]
253,"Dovitinib,PD173074",[Drug]
254,FGFR3:EXPRESSION,[Variant]
255,"Dovitinib,Tyrosine Kinase Inhibitor SU5402,PD173074",[Drug]
256,CBLC,[Gene]
257,CBLC:EXPRESSION,[Variant]
258,PTPRD,[Gene]
259,PTPRD:MUTATION,[Variant]
260,Head And Neck Carcinoma,[Disease]
261,JSI-124,[Drug]
262,DEFA1,[Gene]
263,DEFA1:EXPRESSION,[Variant]
264,Docetaxel,[Drug]
265,ERCC1,[Gene]
266,ERCC1:EXPRESSION,[Variant]
267,NOTCH1:AMPLIFICATION,[Variant]
268,NOTCH1 Antibody (PF-06293622),[Drug]
269,Patritumab,[Drug]
270,WEE1,[Gene]
271,WEE1:RS3910384,[Variant]
272,"Gemcitabine,Platinum Compound",[Drug]
273,FNTB,[Gene]
274,FNTB:RS11623866,[Variant]
275,Lonafarnib,[Drug]
276,PTPRT,[Gene]
277,PTPRT:PROMOTER HYPERMETHYLATION,[Variant]
278,"JSI-124,Stattic",[Drug]
279,VEGFA,[Gene]
280,VEGFA:UNDEREXPRESSION,[Variant]
281,"Bevacizumab,Fluorouracil,Levoleucovorin,Irinotecan",[Drug]
282,DNMT1,[Gene]
283,DNMT1:EXPRESSION,[Variant]
284,Decitabine,[Drug]
285,KRAS:MUTATION,[Variant]
286,PDCD4,[Gene]
287,PDCD4:EXPRESSION,[Variant]
288,MGMT:RS16906252,[Variant]
289,TFF3,[Gene]
290,TFF3:EXPRESSION,[Variant]
291,"Aminoglutethimide,Tamoxifen",[Drug]
292,DKK1,[Gene]
293,DKK1:NUCLEAR EXPRESSION,[Variant]
294,"Levoleucovorin,Fluorouracil,Oxaliplatin,Irinotecan",[Drug]
295,CD44,[Gene]
296,CD44:ISOFORM EXPRESSION,[Variant]
297,RG7356,[Drug]
298,EGF,[Gene]
299,EGF:EXPRESSION,[Variant]
300,MDM2,[Gene]
301,MDM2:EXPRESSION,[Variant]
302,Malignant Pleural Mesothelioma,[Disease]
303,"Cisplatin,Pemetrexed",[Drug]
304,HMOX1,[Gene]
305,HMOX1:EXPRESSION,[Variant]
306,"Sunitinib,Sorafenib",[Drug]
307,SPHK1,[Gene]
308,SPHK1:OVEREXPRESSION,[Variant]
309,CASP8,[Gene]
310,CASP8:EXPRESSION,[Variant]
311,Ewing Sarcoma Of Bone,[Disease]
312,Conatumumab,[Drug]
313,TYMS:EXPRESSION,[Variant]
314,Pemetrexed,[Drug]
315,PBK,[Gene]
316,PBK:OVEREXPRESSION,[Variant]
317,SMARCA4:UNDEREXPRESSION,[Variant]
318,"Cisplatin,Vinorelbine",[Drug]
319,SETBP1,[Gene]
320,SETBP1:EXON 4 MUTATION,[Variant]
321,SETBP1:G870S,[Variant]
322,"Ceritinib,Luminespib,Crizotinib",[Drug]
323,Lorlatinib,[Drug]
324,ALK:EML4-ALK C1156Y-L1198F,[Variant]
325,"Docetaxel,Cetuximab",[Drug]
326,Chemotherapy,[Drug]
327,CDKN1A,[Gene]
328,CDKN1A:EXPRESSION,[Variant]
329,ALCAM,[Gene]
330,ALCAM:EXPRESSION,[Variant]
331,STMN1,[Gene]
332,STMN1:EXPRESSION,[Variant]
333,Endometrial Carcinoma,[Disease]
334,RSF1,[Gene]
335,RSF1:AMPLIFICATION,[Variant]
336,AR:OVEREXPRESSION,[Variant]
337,Dactolisib,[Drug]
338,CDKN1B,[Gene]
339,CDKN1B:CYTOPLASMIC MISLOCALIZATION,[Variant]
340,Anti-ErbB3 Monoclonal Antibody AV-203,[Drug]
341,ERBB3:EXPRESSION,[Variant]
342,AR:V7 EXPRESSION,[Variant]
343,"Enzalutamide,Abiraterone",[Drug]
344,"Lapatinib,Trastuzumab",[Drug]
345,Pancreatic Ductal Adenocarcinoma,[Disease]
346,"Pertuzumab,9F7-F11",[Drug]
347,UGT1A,[Gene]
348,UGT1A:EXPRESSION,[Variant]
349,Ganetespib,[Drug]
350,ERBB4:NUCLEAR TRANSLOCATION,[Variant]
351,ERBB4:EXPRESSION,[Variant]
352,SLFN11,[Gene]
353,SLFN11:EXPRESSION,[Variant]
354,7-Ethyl-10-Hydroxycamptothecin,[Drug]
355,RAC1,[Gene]
356,RAC1:P29S,[Variant]
357,"Dabrafenib,Vemurafenib",[Drug]
358,BIRC5,[Gene]
359,BIRC5:NUCLEAR EXPRESSION,[Variant]
360,"Taxane Compound,Platinum Compound",[Drug]
361,TP53:WILD TYPE,[Variant]
362,"Capecitabine,Cetuximab,Oxaliplatin",[Drug]
363,MRE11,[Gene]
364,MRE11:LOSS,[Variant]
365,Talazoparib,[Drug]
366,Uterine Corpus Endometrial Carcinoma,[Disease]
367,"Afatinib,Trastuzumab,Lapatinib",[Drug]
368,TOP1,[Gene]
369,TOP1:AMPLIFICATION,[Variant]
370,Irinotecan,[Drug]
371,CDKN1B:EXPRESSION,[Variant]
372,"Fluorouracil,Cisplatin",[Drug]
373,AGR2,[Gene]
374,AGR2:EXPRESSION,[Variant]
375,"Temsirolimus,Ridaforolimus",[Drug]
376,"Ridaforolimus,Temsirolimus",[Drug]
377,"Cetuximab,Capecitabine,Oxaliplatin",[Drug]
378,NAPRT,[Gene]
379,NAPRT:PROMOTER HYPERMETHYLATION,[Variant]
380,GNE-617,[Drug]
381,EGFR:EXON 18 OVEREXPRESSION,[Variant]
382,"Bevacizumab,Erlotinib",[Drug]
383,ZEB1,[Gene]
384,ZEB1:EXPRESSION,[Variant]
385,"Gemcitabine,Cytarabine,Doxorubicin",[Drug]
386,"Doxorubicin,Salinomycin",[Drug]
387,TIMP1,[Gene]
388,TIMP1:OVEREXPRESSION,[Variant]
389,Fulvestrant,[Drug]
390,PTP4A3,[Gene]
391,PTP4A3:OVEREXPRESSION,[Variant]
392,TYMS:AMPLIFICATION,[Variant]
393,IGF1R,[Gene]
394,IGF1R:EXPRESSION,[Variant]
395,EPHB4,[Gene]
396,EPHB4:EXPRESSION,[Variant]
397,Bevacizumab,[Drug]
398,Esophageal Carcinoma,[Disease]
399,TYMS:UNDEREXPRESSION,[Variant]
400,TOP2A,[Gene]
401,TOP2A:EXPRESSION,[Variant]
402,TOP1:EXPRESSION,[Variant]
403,"Carboplatin,Topotecan,Cyclophosphamide",[Drug]
404,PRKAA2,[Gene]
405,PRKAA2:T172 PHOSPHORYLATION,[Variant]
406,ACLY SiRNA,[Drug]
407,HSPA5,[Gene]
408,HSPA5:EXPRESSION,[Variant]
409,Anti-EGFR Monoclonal Antibody,[Drug]
410,Pancreatic Carcinoma,[Disease]
411,EIF4EBP1,[Gene]
412,EIF4EBP1:PHOSPHORYLATION,[Variant]
413,KIT:MUTATION,[Variant]
414,"Imatinib,Pictilisib",[Drug]
415,TUBB3,[Gene]
416,TUBB3:EXPRESSION,[Variant]
417,Taxane Compound,[Drug]
418,EGFR:Y1092 PHOSPHORYLATION,[Variant]
419,"Erlotinib,Gefitinib",[Drug]
420,IGF1R:NUCLEAR EXPRESSION,[Variant]
421,Sarcoma,[Disease]
422,IGF1R Monoclonal Antibody,[Drug]
423,CFLAR,[Gene]
424,CFLAR:EXPRESSION,[Variant]
425,PROM1,[Gene]
426,PROM1:EXPRESSION,[Variant]
427,Hepatocellular Carcinoma,[Disease]
428,FOXP3,[Gene]
429,FOXP3:EXPRESSION,[Variant]
430,Epirubicin,[Drug]
431,Raltitrexed,[Drug]
432,RPS6,[Gene]
433,RPS6:PHOSPHORYLATION,[Variant]
434,JAK1,[Gene]
435,JAK1:OVEREXPRESSION,[Variant]
436,Enzastaurin,[Drug]
437,"Dactolisib,WYE354,MTOR Kinase Inhibitor PP242",[Drug]
438,BRCA1:EXPRESSION,[Variant]
439,Malignant Mesothelioma,[Disease]
440,Vinorelbine,[Drug]
441,DUSP6,[Gene]
442,DUSP6:EXPRESSION,[Variant]
443,BRAF:MUTATION,[Variant]
444,HSPB1,[Gene]
445,HSPB1:EXPRESSION,[Variant]
446,Gemcitabine,[Drug]
447,NQO1,[Gene]
448,NQO1:EXPRESSION,[Variant]
449,Amrubicin,[Drug]
450,NQO1:P187S,[Variant]
451,BRCA1:UNDEREXPRESSION,[Variant]
452,"Platinum Compound,Taxane Compound",[Drug]
453,"Immunomodulatory Oligonucleotide,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor",[Drug]
454,ABCB1:EXPRESSION,[Variant]
455,ALK:ALK FUSIONS,[Variant]
456,"Dasatinib,Cetuximab",[Drug]
457,CXCR4,[Gene]
458,CXCR4:EXPRESSION,[Variant]
459,MAGEH1,[Gene]
460,MAGEH1:EXPRESSION,[Variant]
461,Bile Duct Adenocarcinoma,[Disease]
462,ABCC3,[Gene]
463,ABCC3:AMPLIFICATION,[Variant]
464,"Paclitaxel,Monomethyl Auristatin E",[Drug]
465,ABCC10,[Gene]
466,ABCC10:EXPRESSION,[Variant]
467,ASNS,[Gene]
468,ASNS:AMPLIFICATION,[Variant]
469,Asparaginase,[Drug]
470,CDX2,[Gene]
471,CDX2:EXPRESSION,[Variant]
472,STAT3,[Gene]
473,STAT3:SH2 DOMAIN MUTATION,[Variant]
474,T-cell Large Granular Lymphocyte Leukemia,[Disease]
475,POU5F1,[Gene]
476,POU5F1:EXPRESSION,[Variant]
477,Oxaliplatin,[Drug]
478,ERBB2:KINASE DOMAIN MUTATION,[Variant]
479,ERBB2:Y772_A775DUP,[Variant]
480,"Afatinib,Sirolimus",[Drug]
481,Osimertinib,[Drug]
482,EGFR:C797S,[Variant]
483,"Rociletinib,Osimertinib",[Drug]
484,Rindopepimut,[Drug]
485,ERBB2:SERUM LEVELS,[Variant]
486,THBS2,[Gene]
487,THBS2:UNDEREXPRESSION,[Variant]
488,Brain Glioma,[Disease]
489,NTRK1,[Gene]
490,NTRK1:NTRK1 FUSIONS,[Variant]
491,Larotrectinib,[Drug]
492,IDH1:R132H,[Variant]
493,AGI-5198,[Drug]
494,TERT:RS2736100,[Variant]
495,STAG2,[Gene]
496,STAG2:UNDEREXPRESSION,[Variant]
497,HLA-DRA,[Gene]
498,HLA-DRA:EXPRESSION,[Variant]
499,"Nivolumab,Pembrolizumab,Atezolizumab",[Drug]
500,MYD88:L265P,[Variant]
501,Waldenstroem's Macroglobulinemia,[Disease]
502,"Selumetinib,B-Raf/VEGFR-2 Inhibitor RAF265",[Drug]
503,"B-Raf/VEGFR-2 Inhibitor RAF265,Selumetinib",[Drug]
504,"Trametinib,Afatinib",[Drug]
505,"Afatinib,Trametinib",[Drug]
506,MEK Inhibitor RO4987655,[Drug]
507,BRAF:WILD TYPE,[Variant]
508,"Docetaxel,Selumetinib",[Drug]
509,Refametinib,[Drug]
510,NRAS:Q61K,[Variant]
511,"Everolimus,Binimetinib",[Drug]
512,"PI3Kbeta Inhibitor AZD8186,SCH772984",[Drug]
513,"Selumetinib,Teprotumumab",[Drug]
514,"Selumetinib,Dactolisib",[Drug]
515,"Trastuzumab,Lapatinib",[Drug]
516,"Afatinib,Trastuzumab",[Drug]
517,MRE11:FRAMESHIFT MUTATION,[Variant]
518,"Larotrectinib,Lestaurtinib,Crizotinib",[Drug]
519,KIT:EXPRESSION,[Variant]
520,CBFB,[Gene]
521,CBFB:CBFB-MYH11,[Variant]
522,Adrenocortical Carcinoma,[Disease]
523,KMT2A,[Gene]
524,KMT2A:MLL-MLLT3,[Variant]
525,HIF1A,[Gene]
526,HIF1A:3' UTR Polymorphism,[Variant]
527,HIF1A:OVEREXPRESSION,[Variant]
528,EPAS1,[Gene]
529,EPAS1:OVEREXPRESSION,[Variant]
530,VHL:LOSS,[Variant]
531,Renal Carcinoma,[Disease]
532,FLT3:D835,[Variant]
533,"Quizartinib,Ponatinib",[Drug]
534,"Quizartinib,Sorafenib",[Drug]
535,Lung Small Cell Carcinoma,[Disease]
536,"Trastuzumab,Irinotecan",[Drug]
537,Lung Carcinoma,[Disease]
538,Trastuzumab Emtansine,[Drug]
539,PSMB8,[Gene]
540,PSMB8:NUCLEAR EXPRESSION,[Variant]
541,PBK:NUCLEAR EXPRESSION,[Variant]
542,PTTG1,[Gene]
543,PTTG1:OVEREXPRESSION,[Variant]
544,Meningioma,[Disease]
545,LEPR,[Gene]
546,LEPR:UNDEREXPRESSION,[Variant]
547,EGFR:G465R,[Variant]
548,Futuximab/Modotuximab Mixture,[Drug]
549,NEDD9,[Gene]
550,NEDD9:EXPRESSION,[Variant]
551,ETS2,[Gene]
552,ETS2:RS461155,[Variant]
553,"Paclitaxel,Cisplatin",[Drug]
554,KRT18,[Gene]
555,KRT18:UNDEREXPRESSION,[Variant]
556,FGF13,[Gene]
557,FGF13:CYTOPLASMIC EXPRESSION,[Variant]
558,SSX1,[Gene]
559,SSX1:SS18-SSX1,[Variant]
560,Synovial Sarcoma,[Disease]
561,SSX2,[Gene]
562,SSX2:SS18-SSX2,[Variant]
563,Malignant Peripheral Nerve Sheath Tumor,[Disease]
564,SSX4,[Gene]
565,SSX4:SS18-SSX4,[Variant]
566,ABCB1:S893A/T,[Variant]
567,"Pertuzumab,Trastuzumab,Docetaxel",[Drug]
568,"Panitumumab,Futuximab/Modotuximab Mixture",[Drug]
569,EGFR:R451C,[Variant]
570,"Panitumumab,Futuximab/Modotuximab Mixture,Cetuximab",[Drug]
571,EGFR:K467T,[Variant]
572,"Futuximab/Modotuximab Mixture,Panitumumab",[Drug]
573,FCGR2A,[Gene]
574,FCGR2A:H167R,[Variant]
575,FCGR3A,[Gene]
576,FCGR3A:F212V,[Variant]
577,FCGR2B,[Gene]
578,FCGR2B:I232T,[Variant]
579,EGFR:P753S,[Variant]
580,Skin Squamous Cell Carcinoma,[Disease]
581,"Sirolimus,Cetuximab",[Drug]
582,"Tretinoin,Arsenic Trioxide",[Drug]
583,PML:B2 DOMAIN MUTATION,[Variant]
584,PML:PML-RARA A216V,[Variant]
585,PML:PML-RARA L218P,[Variant]
586,MET:EXON 14 MUTATION and AMPLIFICATION,[Variant]
587,Endometrial Serous Adenocarcinoma,[Disease]
588,Patidegib,[Drug]
589,ROS1:CD74-ROS1 G2032R,[Variant]
590,CEBPA:N-TERMINAL FRAME SHIFT,[Variant]
591,OICR-9429,[Drug]
592,FGFR1:ZNF198-FGFR1,[Variant]
593,Myeloproliferative Neoplasm,[Disease]
594,Midostaurin,[Drug]
595,Afimoxifene,[Drug]
596,KDR,[Gene]
597,KDR:A1065T,[Variant]
598,Angiosarcoma,[Disease]
599,KDR:D717V,[Variant]
600,TSC2,[Gene]
601,TSC2:Q1178*,[Variant]
602,Thyroid Gland Carcinoma,[Disease]
603,MTOR:F2108L,[Variant]
604,RAD51D,[Gene]
605,RAD51D:R186*,[Variant]
606,"Tretinoin,Anthracycline Antineoplastic Antibiotic",[Drug]
607,"Trastuzumab,Neratinib",[Drug]
608,ALDH1A2,[Gene]
609,ALDH1A2:EXPRESSION,[Variant]
610,ALDH1A2:UNDEREXPRESSION,[Variant]
611,CIP2A,[Gene]
612,CIP2A:EXPRESSION,[Variant]
613,CIP2A:UNDEREXPRESSION,[Variant]
614,MIR218-1,[Gene]
615,MIR218-1:EXPRESSION,[Variant]
616,Lung Acinar Adenocarcinoma,[Disease]
617,BRCA1:P968FS,[Variant]
618,Hairy Cell Leukemia,[Disease]
619,KRAS:Q22*,[Variant]
620,Colon Mucinous Adenocarcinoma,[Disease]
621,"Capecitabine,Lapatinib",[Drug]
622,"Capecitabine,Trastuzumab",[Drug]
623,DDX43,[Gene]
624,DDX43:OVEREXPRESSION,[Variant]
625,"Trametinib,Selumetinib,MEK Inhibitor PD0325901",[Drug]
626,KIT:RS3733542,[Variant]
627,TBK1,[Gene]
628,TBK1:OVEREXPRESSION,[Variant]
629,"AZ909,Selumetinib",[Drug]
630,"Chemotherapy,Bevacizumab",[Drug]
631,"MEK Inhibitor GDC-0623,G-573",[Drug]
632,Cobimetinib,[Drug]
633,"Selumetinib,Docetaxel",[Drug]
634,STK11:LOSS,[Variant]
635,Adjuvant Chemotherapy,[Drug]
636,HAVCR2,[Gene]
637,HAVCR2:OVEREXPRESSION,[Variant]
638,PD1 Inhibitor,[Drug]
639,"Anti-TIM-3 Monoclonal Antibody,PD1 Inhibitor",[Drug]
640,"Afatinib,Selumetinib",[Drug]
641,"Gefitinib,HER2 Inhibitor CP-724,714,Selumetinib",[Drug]
642,MMP2,[Gene]
643,MMP2:SERUM LEVELS,[Variant]
644,Inflammatory Breast Carcinoma,[Disease]
645,MMP9,[Gene]
646,MMP9:SERUM LEVELS,[Variant]
647,ACTA1,[Gene]
648,ACTA1:EXPRESSION,[Variant]
649,HSPH1,[Gene]
650,HSPH1:NUCLEAR EXPRESSION,[Variant]
651,"Cisplatin,Fluorouracil",[Drug]
652,HSPH1:T17 DELETION,[Variant]
653,"Oxaliplatin,Fluorouracil",[Drug]
654,ECSCR,[Gene]
655,ECSCR:EXPRESSION,[Variant]
656,Angiogenesis Inhibitor,[Drug]
657,ROBO4,[Gene]
658,ROBO4:EXPRESSION,[Variant]
659,"Atezolizumab,Avelumab,Pembrolizumab,Nivolumab",[Drug]
660,PIM1,[Gene]
661,PIM1:NUCLEAR EXPRESSION,[Variant]
662,MDM2:SNP309,[Variant]
663,Head And Neck Cancer,[Disease]
664,Pazopanib,[Drug]
665,Atezolizumab,[Drug]
666,"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,ARS-853",[Drug]
667,"Neratinib,Lapatinib,Trastuzumab",[Drug]
668,Ceritinib,[Drug]
669,"Trastuzumab,Lapatinib,Neratinib",[Drug]
670,ERBB2:L866M,[Variant]
671,"Lapatinib,Neratinib,Trastuzumab",[Drug]
672,ERBB2:S310F/Y,[Variant]
673,Ixazomib,[Drug]
674,AZD5438,[Drug]
675,MIR218-1:UNDEREXPRESSION,[Variant]
676,Pancreatic Cancer,[Disease]
677,Capmatinib,[Drug]
678,WHI-P154,[Drug]
679,ALK:EML4-ALK e20-e20,[Variant]
680,ALK:EML4-ALK e2-e20,[Variant]
681,KDR:R961W,[Variant]
682,Colorectal Adenocarcinoma,[Disease]
683,ALK:EML4-ALK e6-e20,[Variant]
684,"2,4-pyrimidinediamine",[Drug]
685,Retaspimycin Hydrochloride,[Drug]
686,"Retaspimycin Hydrochloride,Crizotinib",[Drug]
687,"Alvespimycin,Crizotinib",[Drug]
688,Alvespimycin,[Drug]
689,TP53:P47S,[Variant]
690,GNAQ,[Gene]
691,GNAQ:MUTATION,[Variant]
692,JQ1,[Drug]
693,GNA11,[Gene]
694,GNA11:MUTATION,[Variant]
695,GNA11:Q209,[Variant]
696,GNAQ:Q209,[Variant]
697,PMS2,[Gene]
698,PMS2:K706FS*19,[Variant]
699,Nivolumab,[Drug]
700,Salirasib,[Drug]
701,"Gemcitabine,Erlotinib",[Drug]
702,KIT:EXON 9 MUTATION,[Variant]
703,"Docetaxel,Trametinib",[Drug]
704,Binimetinib,[Drug]
705,"Trametinib,Metformin",[Drug]
706,PTEN:MUTATION,[Variant]
707,"Panobinostat,Valproic Acid,Vorinostat,Trichostatin A",[Drug]
708,"Vorinostat,Mocetinostat,MC1568",[Drug]
709,FGFR2:MUTATION,[Variant]
710,ALK:MUTATION,[Variant]
711,ALK:NPM-ALK,[Variant]
712,Anaplastic Large Cell Lymphoma,[Disease]
713,ALK:RANBP2-ALK,[Variant]
714,FGFR1:N546K,[Variant]
715,"Foretinib,Cabozantinib",[Drug]
716,"AZD3463,Ceritinib,Crizotinib,Brigatinib",[Drug]
717,ROS1:CD74-ROS1 L2026M,[Variant]
718,ROS1:CD74-ROS1 L2155S,[Variant]
719,"Foretinib,TAE684,Crizotinib",[Drug]
720,ROS1:CD74-ROS1 G2101A,[Variant]
721,ALK:CLTC-ALK,[Variant]
722,U2AF1:MUTATION,[Variant]
723,Myelofibrosis,[Disease]
724,BRAF:DEL 485-490,[Variant]
725,Pan-RAF Inhibitor LY3009120,[Drug]
726,Stomach Carcinoma,[Disease]
727,DUX4,[Gene]
728,DUX4:DUX4 FUSIONS,[Variant]
729,B4GALT1,[Gene]
730,B4GALT1:EXPRESSION,[Variant]
731,BCL2L11,[Gene]
732,BCL2L11:DELETION POLYMORPHISM,[Variant]
733,ALK:ALK FUSION I1171,[Variant]
734,ALK:EML4-ALK  V1180L,[Variant]
735,Brigatinib,[Drug]
736,SIRT1,[Gene]
737,SIRT1:OVEREXPRESSION,[Variant]
738,Pancreatic Ductal Carcinoma,[Disease]
739,Niacinamide,[Drug]
740,KRAS:G12R,[Variant]
741,TP53:P72R,[Variant]
742,PALB2,[Gene]
743,PALB2:BIALLELIC INACTIVATION,[Variant]
744,Mitomycin,[Drug]
745,SMAD4:EXPRESSION,[Variant]
746,FANCC,[Gene]
747,FANCC:LOSS-OF-FUNCTION,[Variant]
748,"Mitomycin,Cisplatin,Chlorambucil,Melphalan,Gemcitabine",[Drug]
749,PDGFRB,[Gene]
750,PDGFRB:EBF1-PDGFRB,[Variant]
751,Malignant Exocrine Pancreas Neoplasm,[Disease]
752,RB1,[Gene]
753,RB1:EXPRESSION,[Variant]
754,MLH1,[Gene]
755,MLH1:METHYLATION,[Variant]
756,PTPN11,[Gene]
757,PTPN11:EXPRESSION,[Variant]
758,Laryngeal Carcinoma,[Disease]
759,FLT3:T227M,[Variant]
760,PALB2:L531FS*30,[Variant]
761,MTOR:S2215Y,[Variant]
762,Endometrial Adenocarcinoma,[Disease]
763,MTOR:C1483Y,[Variant]
764,MTOR:E1799K,[Variant]
765,FGFR2:N550K,[Variant]
766,RB1:OVEREXPRESSION,[Variant]
767,"Gemcitabine,Doxorubicin,Fluorouracil,Mitomycin",[Drug]
768,PPP1R15A,[Gene]
769,PPP1R15A:RS557806,[Variant]
770,"FOLFIRI Regimen,Bevacizumab",[Drug]
771,"Irinotecan,Selumetinib",[Drug]
772,AZD3463,[Drug]
773,ALK:F1245C,[Variant]
774,ALK:DEL4-11,[Variant]
775,ALK:ALK FUSION F1245C,[Variant]
776,ALK:ALK FUSION G1269A,[Variant]
777,"Pictilisib,Tanespimycin",[Drug]
778,"Tanespimycin,Pictilisib",[Drug]
779,"Dactolisib,Cetuximab",[Drug]
780,"Pictilisib,Trametinib,Tanespimycin",[Drug]
781,CDK4:AMPLIFICATION,[Variant]
782,Liposarcoma,[Disease]
783,CDKN2A:LOSS,[Variant]
784,Alvocidib,[Drug]
785,CDKN2B,[Gene]
786,CDKN2B:LOSS,[Variant]
787,CDK4:R24C,[Variant]
788,ASXL1:EXON 12 MUTATION,[Variant]
789,A66,[Drug]
790,Tgx 221,[Drug]
791,CALR,[Gene]
792,CALR:EXON 9 FRAMESHIFT,[Variant]
793,CSF3R,[Gene]
794,CSF3R:MUTATION,[Variant]
795,Chronic Neutrophilic Leukemia,[Disease]
796,Atypical Chronic Myeloid Leukemia,[Disease]
797,EGFR:S768I,[Variant]
798,BRAF:V600K,[Variant]
799,"Cetuximab,Gefitinib,Vemurafenib",[Drug]
800,SMAD4:LOSS,[Variant]
801,"Panitumumab,Vemurafenib",[Drug]
802,SF3B1:K700E,[Variant]
803,Spliceostatin A,[Drug]
804,SF3B1:K666N,[Variant]
805,MAP2K7,[Gene]
806,MAP2K7:E116K,[Variant]
807,"Cobimetinib,Vemurafenib",[Drug]
808,Chronic Leukemia,[Disease]
809,PDGFRA:PDGFRA FUSIONS,[Variant]
810,Chronic Myelomonocytic Leukemia,[Disease]
811,PDGFRB:PDGFRB FUSIONS,[Variant]
812,FGFR1:FGFR1 FUSIONS,[Variant]
813,"Dactolisib,GDC-0879",[Drug]
814,"Omipalisib,Trametinib",[Drug]
815,Gastrointestinal Neuroendocrine Tumor,[Disease]
816,"Dabrafenib,Trametinib,Vemurafenib",[Drug]
817,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",[Disease]
818,JAK2:PCM1-JAK2,[Variant]
819,"Pertuzumab,Docetaxel,Trastuzumab",[Drug]
820,MTOR:E2014K and E2419K,[Variant]
821,Transitional Cell Carcinoma,[Disease]
822,RICTOR,[Gene]
823,RICTOR:AMPLIFICATION,[Variant]
824,"Sapanisertib,Onatasertib",[Drug]
825,PDGFRA:FIP1L1-PDGFRA,[Variant]
826,Bronchiolo-alveolar Adenocarcinoma,[Disease]
827,ROS1:TFG-ROS1,[Variant]
828,PDGFRA:FIP1L1-PDGFRA T674I,[Variant]
829,"Pilaralisib,Trastuzumab",[Drug]
830,BIRC5:OVEREXPRESSION,[Variant]
831,BRAF:D594A,[Variant]
832,"Mitogen-Activated Protein Kinase Kinase Inhibitor,Sorafenib",[Drug]
833,"Trastuzumab,PI3K/BET Inhibitor LY294002",[Drug]
834,BRAF:D594V,[Variant]
835,"Trametinib,Sorafenib",[Drug]
836,BRAF:K483M,[Variant]
837,"Trametinib,Vemurafenib",[Drug]
838,BRAF:L597S,[Variant]
839,"Vemurafenib,Trametinib",[Drug]
840,MEK Inhibitor TAK-733,[Drug]
841,BRAF:L597Q,[Variant]
842,BRAF:K601E,[Variant]
843,BRAF:L597V,[Variant]
844,Taselisib,[Drug]
845,KIT:AMPLIFICATION,[Variant]
846,Mucosal Melanoma,[Disease]
847,NF1,[Gene]
848,NF1:MUTATION,[Variant]
849,"MEK Inhibitor PD0325901,Sirolimus",[Drug]
850,"VTX-11e,AZ628",[Drug]
851,Amuvatinib,[Drug]
852,"Sonidegib,Vismodegib",[Drug]
853,Alemtuzumab,[Drug]
854,Peginterferon Alfa-2a,[Drug]
855,ALK:HIP1-ALK I1171N,[Variant]
856,"Alectinib,Crizotinib",[Drug]
857,ALK:EML4-ALK I1171S,[Variant]
858,BIRC3,[Gene]
859,BIRC3:TRUNCATING MUTATION,[Variant]
860,"Taselisib,Radiation Therapy",[Drug]
861,Ipatasertib,[Drug]
862,GSK126,[Drug]
863,"Paclitaxel,Carboplatin,Sorafenib",[Drug]
864,RAF1,[Gene]
865,RAF1:AMPLIFICATION,[Variant]
866,KRAS:AMPLIFICATION,[Variant]
867,"Docetaxel,Carboplatin,Sorafenib",[Drug]
868,"Capivasertib,Docetaxel",[Drug]
869,"Trastuzumab,Capivasertib",[Drug]
870,"Capivasertib,Lapatinib",[Drug]
871,CEBPA:BIALLELIC INACTIVATION,[Variant]
872,SRSF2,[Gene]
873,SRSF2:MUTATION,[Variant]
874,NRAS:G12/G13,[Variant]
875,RET:OVEREXPRESSION,[Variant]
876,Papillary Adenocarcinoma,[Disease]
877,CTLA4,[Gene]
878,CTLA4:CTLA4-CD28,[Variant]
879,Sezary's Disease,[Disease]
880,Ipilimumab,[Drug]
881,AR:MUTATION,[Variant]
882,"Bicalutamide,Flutamide,Cyproterone Acetate,Nilutamide",[Drug]
883,"Alpelisib,PI3Kbeta Inhibitor AZD8186,Enzalutamide",[Drug]
884,NOTCH1:LOSS-OF-FUNCTION,[Variant]
885,Porcupine Inhibitor WNT974,[Drug]
886,CDK6,[Gene]
887,CDK6:OVEREXPRESSION,[Variant]
888,"Palbociclib,Fulvestrant",[Drug]
889,FLT3:OVEREXPRESSION,[Variant]
890,B-cell Adult Acute Lymphocytic Leukemia,[Disease]
891,Platinum Compound,[Drug]
892,GNAQ:Q209P,[Variant]
893,PTEN:V317FS,[Variant]
894,"MEK Inhibitor CI-1040,Akt Inhibitor MK2206",[Drug]
895,RB1:LOSS-OF-FUNCTION,[Variant]
896,PLX4720,[Drug]
897,ESR1:OVEREXPRESSION,[Variant]
898,"Palbociclib,Letrozole",[Drug]
899,MTOR:M2327I,[Variant]
900,MTOR Kinase Inhibitor AZD8055,[Drug]
901,"Sirolimus,RapaLink-1",[Drug]
902,MTOR:A2034V,[Variant]
903,"RapaLink-1,MTOR Kinase Inhibitor AZD8055",[Drug]
904,Apitolisib,[Drug]
905,BRAF:D594G,[Variant]
906,FLT3:D835H,[Variant]
907,FLT3:D835H/Y,[Variant]
908,"Palbociclib,Trastuzumab",[Drug]
909,JAK1:Q503*,[Variant]
910,Pembrolizumab,[Drug]
911,JAK2:c.1641+1dup,[Variant]
912,B2M,[Gene]
913,B2M:S14FS,[Variant]
914,BRAF:PPFIBP2-BRAF,[Variant]
915,BRAF:KIAA1549-BRAF,[Variant]
916,EGFR:EXPRESSION,[Variant]
917,Langerhans-cell Histiocytosis,[Disease]
918,MET:OVEREXPRESSION,[Variant]
919,"Crizotinib,Vemurafenib",[Drug]
920,POT1,[Gene]
921,POT1:MUTATION,[Variant]
922,MKI67,[Gene]
923,MKI67:EXPRESSION,[Variant]
924,Pseudomyxoma Peritonei,[Disease]
925,RAD23B,[Gene]
926,RAD23B:EXPRESSION,[Variant]
927,Vorinostat,[Drug]
928,"Cetuximab,Vemurafenib",[Drug]
929,"Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor",[Drug]
930,RET:CCDC6-RET,[Variant]
931,Nintedanib,[Drug]
932,MAP2K1:C121S,[Variant]
933,FGFR3:S249C,[Variant]
934,Dovitinib,[Drug]
935,FGFR2:AMPLIFICATION,[Variant]
936,FGF3,[Gene]
937,FGF3:AMPLIFICATION,[Variant]
938,"Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor",[Drug]
939,VHL:R200W (c.598C>T),[Variant]
940,Chuvash Polycythemia,[Disease]
941,Ruxolitinib,[Drug]
942,RB1:PHOSPHORYLATION,[Variant]
943,"Everolimus,MTOR Kinase Inhibitor PP242",[Drug]
944,PIK3R1,[Gene]
945,PIK3R1:MUTATION,[Variant]
946,MTOR Kinase Inhibitor PP242,[Drug]
947,"Ipilimumab,Nivolumab",[Drug]
948,STK11:D194E,[Variant]
949,Peutz-Jeghers Syndrome,[Disease]
950,"Sirolimus,Everolimus",[Drug]
951,AKT2:AMPLIFICATION,[Variant]
952,"Vandetanib,Everolimus",[Drug]
953,"Fulvestrant,Everolimus",[Drug]
954,"Temsirolimus,Perifosine",[Drug]
955,"Perifosine,Temsirolimus",[Drug]
956,PTEN:R130*,[Variant]
957,FBXW7:LOSS-OF-FUNCTION,[Variant]
958,RB1:M695FS*26,[Variant]
959,JUN,[Gene]
960,JUN:OVEREXPRESSION,[Variant]
961,Irbesartan,[Drug]
962,FOS,[Gene]
963,FOS:OVEREXPRESSION,[Variant]
964,Colon Adenocarcinoma,[Disease]
965,CDKN2A:RS3814960,[Variant]
966,MDM2:RS34886328,[Variant]
967,CBLB,[Gene]
968,CBLB:RS2305035,[Variant]
969,PRDM1,[Gene]
970,PRDM1:MUTATION,[Variant]
971,IDH1:MUTATION,[Variant]
972,"IMG-2005-5,IRAK-1/4 Inhibitor",[Drug]
973,"Refametinib,Sorafenib",[Drug]
974,Mixed Fibrolamellar Hepatocellular Carcinoma,[Disease]
975,SMAD4:DELETION,[Variant]
976,LRP1B:DELETION,[Variant]
977,ATRX,[Gene]
978,ATRX:UNDEREXPRESSION,[Variant]
979,"PCV Regimen,Temozolomide",[Drug]
980,MET:D1228N,[Variant]
981,CASP8:D302H,[Variant]
982,AXL,[Gene]
983,AXL:EXPRESSION,[Variant]
984,GAS6,[Gene]
985,GAS6:EXPRESSION,[Variant]
986,ETV4,[Gene]
987,ETV4:OVEREXPRESSION,[Variant]
988,STAG3,[Gene]
989,STAG3:UNDEREXPRESSION,[Variant]
990,MAP2K1:Q56_V60del,[Variant]
991,BRAF:BRAF-CUL1,[Variant]
992,Mitogen-Activated Protein Kinase Kinase Inhibitor,[Drug]
993,BRAF:ZKSCAN1-BRAF,[Variant]
994,"Temsirolimus,Bevacizumab,Sorafenib",[Drug]
995,"Erlotinib,Gefitinib,Afatinib",[Drug]
996,BRAF:L505H,[Variant]
997,"Erlotinib,Afatinib,Gefitinib",[Drug]
998,HIF1A:EXPRESSION,[Variant]
999,"Cediranib,Olaparib",[Drug]
1000,BRCA2:D3095E,[Variant]
1001,MLH1:EXPRESSION,[Variant]
1002,BCOR,[Gene]
1003,BCOR:MUTATION,[Variant]
1004,CDH1,[Gene]
1005,CDH1:MUTATION,[Variant]
1006,RHOA,[Gene]
1007,RHOA:MUTATION,[Variant]
1008,Triple-receptor Negative Breast Cancer,[Disease]
1009,Scrotum Paget's Disease,[Disease]
1010,ERBB2:MUTATION,[Variant]
1011,MEN1,[Gene]
1012,MEN1:FRAMESHIFT TRUNCATION,[Variant]
1013,Thyroid Gland Hurthle Cell Carcinoma,[Disease]
1014,KMT2C,[Gene]
1015,KMT2C:MUTATION,[Variant]
1016,STAG2:MUTATION,[Variant]
1017,EGFR:MUTATION,[Variant]
1018,MYCL,[Gene]
1019,MYCL:EXPRESSION,[Variant]
1020,"I-BET151,JQ1",[Drug]
1021,HGF,[Gene]
1022,HGF:EXPRESSION,[Variant]
1023,MET Tyrosine Kinase Inhibitor SGX523,[Drug]
1024,SOX10,[Gene]
1025,SOX10:LOSS,[Variant]
1026,FGF2,[Gene]
1027,FGF2:EXPRESSION,[Variant]
1028,Quizartinib,[Drug]
1029,EIF1AX,[Gene]
1030,EIF1AX:MUTATION,[Variant]
1031,PAX8:EXPRESSION,[Variant]
1032,Female Reproductive Organ Cancer,[Disease]
1033,ERRFI1,[Gene]
1034,ERRFI1:E384*,[Variant]
1035,Systemic Mastocytosis,[Disease]
1036,ESR1:S463P,[Variant]
1037,Aromatase Inhibitor,[Drug]
1038,SGK1,[Gene]
1039,SGK1:OVEREXPRESSION,[Variant]
1040,"Alpelisib,SGK1-Inh",[Drug]
1041,CDK Inhibitor SNS-032,[Drug]
1042,Ovarian Serous Cystadenocarcinoma,[Disease]
1043,"Dinaciclib,Akt Inhibitor MK2206",[Drug]
1044,BRAF:G596C,[Variant]
1045,"Trametinib,Dabrafenib",[Drug]
1046,SMARCB1,[Gene]
1047,SMARCB1:UNDEREXPRESSION,[Variant]
1048,Tazemetostat,[Drug]
1049,SMARCB1:DELETION,[Variant]
1050,Rhabdoid Cancer,[Disease]
1051,NF2:LOSS,[Variant]
1052,NF1:LOSS,[Variant]
1053,JQ1 Compound,[Drug]
1054,SH2B3,[Gene]
1055,SH2B3:RS3184504,[Variant]
1056,KIF23,[Gene]
1057,KIF23:EXPRESSION,[Variant]
1058,ERBB3:V104M,[Variant]
1059,ERBB3:R103G,[Variant]
1060,ERBB3:G284R,[Variant]
1061,GADD45A,[Gene]
1062,GADD45A:rs681673,[Variant]
1063,EWSR1,[Gene]
1064,EWSR1:EWSR1-FLI1,[Variant]
1065,Rectum Cancer,[Disease]
1066,BRCA2:TRUNCATING MUTATION,[Variant]
1067,BRCA1:Alu insertion,[Variant]
1068,HOXB13,[Gene]
1069,HOXB13:G84E,[Variant]
1070,KLLN,[Gene]
1071,KLLN:PROMOTER METHYLATION,[Variant]
1072,EGFR:D761Y,[Variant]
1073,Her2-receptor Negative Breast Cancer,[Disease]
1074,CRBN,[Gene]
1075,CRBN:MUTATION,[Variant]
1076,"Lenalidomide,Pomalidomide",[Drug]
1077,TSC1:R1062W,[Variant]
1078,Tuberous Sclerosis,[Disease]
1079,STK11:MUTATION,[Variant]
1080,PDGFRA:AMPLIFICATION,[Variant]
1081,DDIT3,[Gene]
1082,DDIT3:EWSR1-DDIT3,[Variant]
1083,Myxoid Liposarcoma,[Disease]
1084,EGFR:G719,[Variant]
1085,BRD4,[Gene]
1086,BRD4:BRD4-NUTM1,[Variant]
1087,NUT Midline Carcinoma,[Disease]
1088,EGFR:S720,[Variant]
1089,CYP2D6,[Gene]
1090,CYP2D6:LOSS-OF-FUNCTION,[Variant]
1091,DDIT3:FUS-DDIT3,[Variant]
1092,EGFR:K757R,[Variant]
1093,EGFR:E746G,[Variant]
1094,MLH1:E13FS*3,[Variant]
1095,Lynch Syndrome,[Disease]
1096,MSH2,[Gene]
1097,MSH2:R383*,[Variant]
1098,MLH1:V534R,[Variant]
1099,UGT1A1,[Gene]
1100,UGT1A1:UGT1A1*28,[Variant]
1101,Belinostat,[Drug]
1102,MLH1:G606FS*2,[Variant]
1103,MLH1:c.790+1G>A,[Variant]
1104,UGT1A1:UGT1A1*60,[Variant]
1105,MLH1:K618DEL,[Variant]
1106,MLH1:R687FS,[Variant]
1107,EGFR:V769_770insASV,[Variant]
1108,DPYD,[Gene]
1109,DPYD:DPYD*2A HOMOZYGOSITY,[Variant]
1110,"Capecitabine,Fluorouracil,Tegafur",[Drug]
1111,DPYD:DPYD*13 HOMOZYGOSITY,[Variant]
1112,"Tegafur,Fluorouracil,Capecitabine",[Drug]
1113,FOS:TRUNCATING FUSION,[Variant]
1114,Bone Epithelioid Hemangioma,[Disease]
1115,DPYD:RS67376798 HOMOZYGOSITY,[Variant]
1116,"Tegafur,Capecitabine,Fluorouracil",[Drug]
1117,MLH1:R100*,[Variant]
1118,WWTR1,[Gene]
1119,WWTR1:WWTR1-CAMTA1,[Variant]
1120,Malignant Epithelioid Hemangioendothelioma,[Disease]
1121,MLH1:T117M,[Variant]
1122,MLH1:Q426FS,[Variant]
1123,MLH1:V49A,[Variant]
1124,EGFR:EXON 20 INSERTION,[Variant]
1125,MLH1:D667FS,[Variant]
1126,MLH1:M1L,[Variant]
1127,MLH1:*757L,[Variant]
1128,MLH1:R265G,[Variant]
1129,MLH1:V213FS,[Variant]
1130,MLH1:N551T,[Variant]
1131,MLH1:A424T,[Variant]
1132,MLH1:Q149*,[Variant]
1133,MLH1:R226*,[Variant]
1134,MLH1:P536FS,[Variant]
1135,MLH1:G67R,[Variant]
1136,MLH1:I68S,[Variant]
1137,MLH1:G65D,[Variant]
1138,MLH1:A681V,[Variant]
1139,MSH6,[Gene]
1140,MSH6:P138T,[Variant]
1141,MSH2:V273FS,[Variant]
1142,MSH2:E28FS,[Variant]
1143,VHL:E55FS (c.163_164delGA),[Variant]
1144,Von Hippel-Lindau Disease,[Disease]
1145,MSH6:I891FS,[Variant]
1146,VHL:E55RfsTer11 (c.163delG),[Variant]
1147,MSH6:R1242H,[Variant]
1148,MLH1:M490T,[Variant]
1149,MSH2:K172*,[Variant]
1150,VHL:A56FS (c.164_165insG),[Variant]
1151,MSH2:E483G,[Variant]
1152,PDGFRA:TNKS2-PDGFRA,[Variant]
1153,MSH6:V352I,[Variant]
1154,MSH6:R1242C,[Variant]
1155,SLCO1B1,[Gene]
1156,SLCO1B1:RS4149056,[Variant]
1157,Methotrexate,[Drug]
1158,SLCO1B1:N130D,[Variant]
1159,TYMS:RS34743033,[Variant]
1160,GLI1,[Gene]
1161,GLI1:ACTB-GLI1,[Variant]
1162,Pericytoma,[Disease]
1163,ERBB3:V855A,[Variant]
1164,"Pertuzumab,Afatinib",[Drug]
1165,FGFR2:FGFR2-BICC1,[Variant]
1166,FGFR2:FGFR2-AHCYL1,[Variant]
1167,CDKN2B:METHYLATION,[Variant]
1168,CHEK2:1100DELC,[Variant]
1169,"PD173074,Infigratinib",[Drug]
1170,CHEK2:I157T,[Variant]
1171,CHEK2:IVS2+1G>A,[Variant]
1172,PTPRD:V253I,[Variant]
1173,"Teprotumumab,Cixutumumab",[Drug]
1174,VHL:A56fs (c.164_165insA),[Variant]
1175,VHL:E55= (c.165G>A),[Variant]
1176,RRM1,[Gene]
1177,RRM1:OVEREXPRESSION,[Variant]
1178,RRM2,[Gene]
1179,RRM2:OVEREXPRESSION,[Variant]
1180,POLE,[Gene]
1181,POLE:MUTATION,[Variant]
1182,MET:D1228V,[Variant]
1183,Savolitinib,[Drug]
1184,RB1:MUTATION,[Variant]
1185,NTRK1:SQSTM1-NTRK1,[Variant]
1186,Entrectinib,[Drug]
1187,NTRK3,[Gene]
1188,NTRK3:ETV6-NTRK3,[Variant]
1189,Salivary Gland Carcinoma,[Disease]
1190,RUNX1:K83E,[Variant]
1191,RUNX1:Y260*,[Variant]
1192,RUNX1:R135FSX177,[Variant]
1193,NTRK3:ETV6-NTRK3 G623R,[Variant]
1194,RUNX1:D198Y,[Variant]
1195,RUNX1:A107P,[Variant]
1196,MSH2:LOSS,[Variant]
1197,"Anti-PD-1 Monoclonal Antibody MEDI0680,Durvalumab",[Drug]
1198,MSH6:LOSS,[Variant]
1199,"Palbociclib,Linsitinib",[Drug]
1200,Dermatofibrosarcoma Protuberans,[Disease]
1201,RUNX1:T148HFSX9,[Variant]
1202,DDX41,[Gene]
1203,DDX41:R164W,[Variant]
1204,ERBB2:G776L,[Variant]
1205,ERBB2:G778_P780DUP,[Variant]
1206,ERBB2:M774DELINSWLV,[Variant]
1207,PTPRB,[Gene]
1208,PTPRB:LOSS-OF-FUNCTION,[Variant]
1209,VHL:A149S (c.445G>T),[Variant]
1210,Rucaparib,[Drug]
1211,Therapeutic Tumor Infiltrating Lymphocytes,[Drug]
1212,HLA-C,[Gene]
1213,HLA-C:COPY-NEUTRAL LOSS OF HETEROZYGOSITY,[Variant]
1214,JAK1:S703I,[Variant]
1215,EPCAM,[Gene]
1216,EPCAM:3' EXON DELETION,[Variant]
1217,"Vemurafenib,Irinotecan,Cetuximab",[Drug]
1218,ARAF:S490T,[Variant]
1219,"Irinotecan,Vemurafenib,Cetuximab",[Drug]
1220,GNAS,[Gene]
1221,GNAS:R201C,[Variant]
1222,"Cetuximab,Vemurafenib,Irinotecan",[Drug]
1223,FGFR3:MUTATION,[Variant]
1224,FGFR2:FGFR2 fusions,[Variant]
1225,VHL:M54IFS (c.162_166delGGAGG),[Variant]
1226,Erdafitinib,[Drug]
1227,FGFR3:FGFR3-TACC3,[Variant]
1228,AKT3,[Gene]
1229,AKT3:OVEREXPRESSION,[Variant]
1230,Pan-AKT Kinase Inhibitor GSK690693,[Drug]
1231,"Pol I Inhibitor CX5461,Quarfloxin",[Drug]
1232,PTEN:R173C,[Variant]
1233,Endometrial Hyperplasia,[Disease]
1234,PTEN Hamartoma Tumor Syndrome,[Disease]
1235,ALK:ALTERNATIVE TRANSCRIPT (ATI),[Variant]
1236,VHL:EXON 1-3 DELETION,[Variant]
1237,VHL:EXON 1 DELETION,[Variant]
1238,VHL:EXON 1-2 DELETION,[Variant]
1239,VHL:M1FS (c.1_17del17),[Variant]
1240,VHL:M1? (c.1-1_20del21),[Variant]
1241,VHL:M1? (c.3G>A),[Variant]
1242,VHL:N7D (c.19A>G),[Variant]
1243,VHL:P25L (c.74C>T),[Variant]
1244,VHL:P59fs (c.173_174insC),[Variant]
1245,VHL:Y98FS (c.291_310del20),[Variant]
1246,"Sotrastaurin Acetate,MEK Inhibitor PD0325901",[Drug]
1247,Plexiform Neurofibroma,[Disease]
1248,NTRK1:EXPRESSION,[Variant]
1249,PDGFRA:P577S,[Variant]
1250,"Crenolanib,Imatinib",[Drug]
1251,PDGFRA:R841K,[Variant]
1252,"Imatinib,Crenolanib",[Drug]
1253,PDGFRA:H845Y,[Variant]
1254,PDGFRA:G853D,[Variant]
1255,"Cetuximab,Crizotinib",[Drug]
1256,MTAP,[Gene]
1257,MTAP:Underexpression,[Variant]
1258,Pyrimidine Antagonist,[Drug]
1259,VPS37A,[Gene]
1260,VPS37A:UNDEREXPRESSION,[Variant]
1261,Chordoma,[Disease]
1262,BTK:T316A,[Variant]
1263,ERBB2:T862A,[Variant]
1264,ERBB2:V773A,[Variant]
1265,ERBB2:N857S,[Variant]
1266,ERBB2:H878Y,[Variant]
1267,FGFR Inhibitor AZD4547,[Drug]
1268,ERBB2:OVEREXPRESSION,[Variant]
1269,GNAS:R201,[Variant]
1270,GNAS:c.393T>C,[Variant]
1271,Intrahepatic Cholangiocarcinoma,[Disease]
1272,Breast Carcinoma,[Disease]
1273,PIK3CA:C420R,[Variant]
1274,NRAS:G12D,[Variant]
1275,"Cetuximab,Irinotecan",[Drug]
1276,Melphalan,[Drug]
1277,Malignant Glioma,[Disease]
1278,"Bevacizumab,Sunitinib",[Drug]
1279,Pictilisib Bismesylate,[Drug]
1280,PIK3CA:WILD TYPE,[Variant]
1281,Aspirin,[Drug]
1282,PI103,[Drug]
1283,PIK3CA:RARE MUTATION,[Variant]
1284,"Oxaliplatin,Bevacizumab,Capecitabine",[Drug]
1285,EGFR:Ex19 del L858R,[Variant]
1286,Canertinib,[Drug]
1287,ABL1:BCR-ABL F359V,[Variant]
1288,Nilotinib,[Drug]
1289,"Cetuximab,Chemotherapy",[Drug]
1290,PIK3CA:Q546K,[Variant]
1291,"Irinotecan,Cetuximab",[Drug]
1292,NRAS:G13R,[Variant]
1293,KRAS:A146T,[Variant]
1294,PIK3CA:E545Q,[Variant]
1295,ATM:T2666A,[Variant]
1296,ATM:R3008C,[Variant]
1297,ATM:c.902-1G>T,[Variant]
1298,KRAS:A146P,[Variant]
1299,KRAS:G12S,[Variant]
1300,TP53:R273L,[Variant]
1301,"Etoposide,Cisplatin,Mitomycin",[Drug]
1302,TP53:Y220C,[Variant]
1303,"Cisplatin,Etoposide,Mitomycin",[Drug]
1304,EAP Protocol,[Drug]
1305,Ivosidenib,[Drug]
1306,BPTES,[Drug]
1307,KIT:T417_D419delinsY,[Variant]
1308,KIT:F506_F508DUP,[Variant]
1309,KIT:N822H,[Variant]
1310,KIT:N822K,[Variant]
1311,PDGFRA:V561D,[Variant]
1312,PDGFRA:D842_H845DELDIMH,[Variant]
1313,KIT:K484_G487DEL,[Variant]
1314,KIT:V560G,[Variant]
1315,KIT:K642E,[Variant]
1316,KIT:EXON 13 MUTATION,[Variant]
1317,KIT:W557_K558DELWK,[Variant]
1318,KIT:Y503_F504insAY,[Variant]
1319,PDGFRA:EXON 18 MUTATION,[Variant]
1320,KIT:D579DEL,[Variant]
1321,EGFR:G719A,[Variant]
1322,EGFR:WILDTYPE,[Variant]
1323,EGFR:E746_A750del,[Variant]
1324,ABL1:BCR-ABL M244V,[Variant]
1325,ABL1:BCR-ABL L248V,[Variant]
1326,"Nilotinib,Imatinib Mesylate,Dasatinib",[Drug]
1327,ABL1:BCR-ABL G250E,[Variant]
1328,ABL1:BCR-ABL Q252H,[Variant]
1329,ABL1:BCR-ABL Y253H,[Variant]
1330,"Nilotinib,Imatinib Mesylate",[Drug]
1331,ABL1:Y253F,[Variant]
1332,ABL1:BCR-ABL E255V,[Variant]
1333,ABL1:BCR-ABL D276G,[Variant]
1334,ABL1:BCR-ABL E355G,[Variant]
1335,"Bafetinib,Nilotinib",[Drug]
1336,ABL1:S417Y,[Variant]
1337,ABL1:BCR-ABL M351T,[Variant]
1338,ABL1:BCR-ABL H396R,[Variant]
1339,TP53:OVEREXPRESSION,[Variant]
1340,TP53:Y234C,[Variant]
1341,TP53:ALTERATION,[Variant]
1342,"Mitomycin,Cisplatin,Etoposide",[Drug]
1343,TP53:R282L,[Variant]
1344,TP53:R213P,[Variant]
1345,"Cisplatin,Etoposide,Doxorubicin",[Drug]
1346,ABL1:BCR-ABL F486S,[Variant]
1347,ATM:c.7089+1del,[Variant]
1348,ATM:c.7515+1_2del,[Variant]
1349,ATM:K293*,[Variant]
1350,ATM:F1025L,[Variant]
1351,ATM:D1930V,[Variant]
1352,ATM:E2187*,[Variant]
1353,ATM:L2427P,[Variant]
1354,ATM:F2732V,[Variant]
1355,ATM:K468FS,[Variant]
1356,ATM:D1682H,[Variant]
1357,ATM:A2062V,[Variant]
1358,ATM:C2488Y,[Variant]
1359,"Imatinib Mesylate,Nilotinib",[Drug]
1360,ABL1:BCR-ABL E292V,[Variant]
1361,ABL1:BCR-ABL F359C,[Variant]
1362,ABL1:BCR-ABL L384M,[Variant]
1363,ABL1:BCR-ABL V299L,[Variant]
1364,ABL1:BCR-ABL L387F,[Variant]
1365,ABL1:BCR-ABL G398R,[Variant]
1366,PIK3CA:K111N,[Variant]
1367,PIK3CA:I391M,[Variant]
1368,BRCA1:Q1467*,[Variant]
1369,BRCA2:M1R,[Variant]
1370,BRCA2:M1I,[Variant]
1371,BRCA2:V159M,[Variant]
1372,BRCA2:V211L,[Variant]
1373,BRCA2:V211I,[Variant]
1374,BRCA2:R2336P,[Variant]
1375,KIT:D820Y,[Variant]
1376,Bladder Urothelial Carcinoma,[Disease]
1377,Esophageal Cancer,[Disease]
1378,MGMT:UNDEREXPRESSION,[Variant]
1379,Neuroendocrine Tumor,[Disease]
1380,RRM1:UNDEREXPRESSION,[Variant]
1381,"Cisplatin,Gemcitabine",[Drug]
1382,"Trametinib,Selumetinib",[Drug]
1383,RET:C609Y,[Variant]
1384,"FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074,Infigratinib,FGFR Inhibitor AZD4547",[Drug]
1385,KIT:Y823D,[Variant]
1386,KIT:C809G,[Variant]
1387,KIT:D820A,[Variant]
1388,KIT:D820G,[Variant]
1389,KIT:D816H,[Variant]
1390,KIT:T670I,[Variant]
1391,"Nivolumab,Atezolizumab,Pembrolizumab",[Drug]
1392,BRAF:AMPLIFICATION,[Variant]
1393,"Panitumumab,Dabrafenib",[Drug]
1394,"Binimetinib,Ribociclib",[Drug]
1395,ROS1:G2032R,[Variant]
1396,MAP2K1:K57N,[Variant]
1397,CTAG1B,[Gene]
1398,CTAG1B:OVEREXPRESSION,[Variant]
1399,Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced C259 T Lymphocytes GSK3377794,[Drug]
1400,CTAG2,[Gene]
1401,CTAG2:OVEREXPRESSION,[Variant]
1402,NTRK3:NTRK3 FUSIONS,[Variant]
1403,NTRK1:LMNA-NTRK1 e2-e11,[Variant]
1404,NTRK1:AMPLIFICATION,[Variant]
1405,NTRK3:AMPLIFICATION,[Variant]
1406,NTRK1:LMNA-NTRK1 e11-e10,[Variant]
1407,NTRK1:LMNA-NTRK1 G595R and G667C,[Variant]
1408,Nutlin-3a,[Drug]
1409,AMGMDS3,[Drug]
1410,Leukemia,[Disease]
1411,RG7112,[Drug]
1412,DCC,[Gene]
1413,DCC:EXPRESSION,[Variant]
1414,CTNNB1,[Gene]
1415,CTNNB1:T41A,[Variant]
1416,Desmoid Tumor,[Disease]
1417,CTNNB1:S45F,[Variant]
1418,CTNNB1:S45P,[Variant]
1419,ARID1A,[Gene]
1420,ARID1A:LOSS-OF-FUNCTION,[Variant]
1421,Ovarian Clear Cell Carcinoma,[Disease]
1422,Cervix Carcinoma,[Disease]
1423,ALK:F1245V,[Variant]
1424,CTNNB1:ACTIVATING MUTATION,[Variant]
1425,"Anti-PD-L1 Monoclonal Antibody,Anti-CTLA-4 Monoclonal Antibody",[Drug]
1426,MERTK,[Gene]
1427,MERTK:OVEREXPRESSION,[Variant]
1428,UNC1062,[Drug]
1429,TP53:CONSERVED DOMAIN MUT,[Variant]
1430,Radiation Therapy,[Drug]
1431,MYC,[Gene]
1432,MYC:OVEREXPRESSION,[Variant]
1433,"Olaparib,Prexasertib,Cisplatin",[Drug]
1434,FLT3:D835V,[Variant]
1435,Tandutinib,[Drug]
1436,"Cytarabine,Sunitinib",[Drug]
1437,"Sunitinib,Daunorubicin",[Drug]
1438,"Osimertinib,Rociletinib",[Drug]
1439,KIT:V559D,[Variant]
1440,"Dasatinib,Sunitinib,PD-180970,Tandutinib,Imatinib",[Drug]
1441,"Tyrphostin AG 1296,AS602868",[Drug]
1442,GNAS:R201H,[Variant]
1443,Radioactive Iodine,[Drug]
1444,BRAF:Non-V600,[Variant]
1445,NRAS:Q61H,[Variant]
1446,"Teprotumumab,Erlotinib",[Drug]
1447,PIK3CA:E545G,[Variant]
1448,"Cetuximab,FOLFOX-4 Regimen",[Drug]
1449,Childhood Pilocytic Astrocytoma,[Disease]
1450,EGFR:L861Q,[Variant]
1451,"Erlotinib,Multikinase Inhibitor AEE788,Gefitinib",[Drug]
1452,"Multikinase Inhibitor AEE788,Gefitinib,Erlotinib",[Drug]
1453,Bosutinib,[Drug]
1454,Axitinib,[Drug]
1455,PIK3CA:R88Q,[Variant]
1456,NRAS:G12C,[Variant]
1457,PIK3CA:G1049R,[Variant]
1458,KRAS:Q61H,[Variant]
1459,KRAS:Q61L,[Variant]
1460,KRAS:Q61R,[Variant]
1461,KRAS:Q61K,[Variant]
1462,KRAS:A146,[Variant]
1463,PIK3CA:N345K,[Variant]
1464,KIT:V560_L576DEL,[Variant]
1465,KIT:K550_K558del,[Variant]
1466,KIT:V560D,[Variant]
1467,"Imatinib,Ponatinib",[Drug]
1468,"Regorafenib,Sunitinib",[Drug]
1469,KIT:K558_V559del,[Variant]
1470,KIT:A502_Y503insAY,[Variant]
1471,BRAF:EXON 15 MUTATION,[Variant]
1472,KIT:P551_E554delPMYE,[Variant]
1473,"Regorafenib,Imatinib,Ponatinib,Sunitinib",[Drug]
1474,"Imatinib,Dasatinib",[Drug]
1475,KIT:WILDTYPE,[Variant]
1476,EGFR:R108K,[Variant]
1477,EGFR:T263P,[Variant]
1478,EGFR:A289V,[Variant]
1479,EGFR:V742A,[Variant]
1480,EGFR:E746_T751>I,[Variant]
1481,EGFR:G719D,[Variant]
1482,EGFR:L747P,[Variant]
1483,EGFR:V774A,[Variant]
1484,EGFR:V774M,[Variant]
1485,EGFR:K806E,[Variant]
1486,EGFR:N826Y,[Variant]
1487,EGFR:V834I,[Variant]
1488,EGFR:L838P,[Variant]
1489,EGFR:N842S,[Variant]
1490,EGFR:T847I,[Variant]
1491,EGFR:V851I,[Variant]
1492,EGFR:L747_P753delinsS,[Variant]
1493,EGFR:D770_N771insSVD,[Variant]
1494,EGFR:H773_V774insH,[Variant]
1495,EGFR:R831H,[Variant]
1496,EGFR:L838V,[Variant]
1497,EGFR:L861,[Variant]
1498,EGFR:E868G,[Variant]
1499,ABL1:BCR-ABL L387M,[Variant]
1500,PIK3CA:H1047L,[Variant]
1501,ABL1:BCR-ABL L364I,[Variant]
1502,"Imatinib,Regorafenib,Sunitinib",[Drug]
1503,"Ponatinib,Regorafenib,Imatinib",[Drug]
1504,PIK3CA:S158L,[Variant]
1505,PIK3CA:E81K,[Variant]
1506,"Cetuximab,Oxaliplatin,Fluorouracil",[Drug]
1507,PIK3CA:R93W,[Variant]
1508,EGFR:R776C,[Variant]
1509,ABL1:L298V,[Variant]
1510,ABL1:BCR-ABL F311I,[Variant]
1511,ABL1:BCR-ABL E453Q,[Variant]
1512,ARID1A:Q456*,[Variant]
1513,EGFR:H773_V774insNPH,[Variant]
1514,EGFR:D770_N771insGL,[Variant]
1515,EGFR:A864T,[Variant]
1516,EGFR:N826S,[Variant]
1517,EGFR:A763_Y764insFQEA,[Variant]
1518,AKT3:E17K,[Variant]
1519,ABL1:BCR-ABL F359I,[Variant]
1520,ABL1:BCR-ABL M343T,[Variant]
1521,ABL1:BCR-ABL F317V,[Variant]
1522,ABL1:BCR-ABL E279K,[Variant]
1523,ABL1:BCR-ABL Q300R,[Variant]
1524,ABL1:BCR-ABL F311L,[Variant]
1525,ABL1:BCR-ABL N331S,[Variant]
1526,ABL1:BCR-ABL L364P,[Variant]
1527,ABL1:BCR-ABL H396P,[Variant]
1528,ABL1:BCR-ABL D421G,[Variant]
1529,ABL1:BCR-ABL E450V,[Variant]
1530,ABL1:BCR-ABL E453K,[Variant]
1531,ABL1:BCR-ABL E453A,[Variant]
1532,ABL1:BCR-ABL P480A,[Variant]
1533,KIT:K550_W557del,[Variant]
1534,"Imatinib,Ponatinib,Sunitinib,Regorafenib",[Drug]
1535,KIT:K558NP,[Variant]
1536,"Imatinib,Regorafenib,Ponatinib,Sunitinib",[Drug]
1537,KIT:V569_L576DEL,[Variant]
1538,BRCA1:W1815X,[Variant]
1539,Endometrioid Ovary Carcinoma,[Disease]
1540,"Regorafenib,Imatinib,Ponatinib",[Drug]
1541,KIT:D816E,[Variant]
1542,"Imatinib,Sunitinib",[Drug]
1543,EGFR:D770_N771insGT,[Variant]
1544,SMO:L412F,[Variant]
1545,EGFR:W731L,[Variant]
1546,EGFR:E734Q,[Variant]
1547,EGFR:T785A,[Variant]
1548,EGFR:C797Y,[Variant]
1549,EGFR:Y801H,[Variant]
1550,EGFR:A767_V769dupASV,[Variant]
1551,EGFR:L747_S752delinsQ,[Variant]
1552,EGFR:L861R,[Variant]
1553,ABL1:BCR-ABL D363G,[Variant]
1554,ABL1:BCR-ABL V379I,[Variant]
1555,ABL1:BCR-ABL A397P,[Variant]
1556,ABL1:BCR-ABL E98G,[Variant]
1557,BRAF:G596R,[Variant]
1558,EGFR:RARE Exon 18-21 Mutation,[Variant]
1559,ABL1:C475V,[Variant]
1560,ABL1:BCR-ABL N336S,[Variant]
1561,POLD1,[Gene]
1562,POLD1:C284Y,[Variant]
1563,POLD1:E374K,[Variant]
1564,PIK3R2,[Gene]
1565,PIK3R2:N561D,[Variant]
1566,PIK3CA:D350G,[Variant]
1567,NRAS:Q179X,[Variant]
1568,ABL1:R351W,[Variant]
1569,ABL1:G340L,[Variant]
1570,"Imatinib Mesylate,Dasatinib",[Drug]
1571,KIT:S628N,[Variant]
1572,EGFR:M766_A767insAI,[Variant]
1573,EGFR:Y764_V765insHH,[Variant]
1574,EGFR:D770_N771insGY,[Variant]
1575,EGFR:P772_H773insYNP,[Variant]
1576,EGFR:P772_V774insPHV,[Variant]
1577,JAK2:F547 SPLICE SITE MUTATION,[Variant]
1578,ARID1A:P1175FS*5,[Variant]
1579,Anti-VEGF Monoclonal Antibody,[Drug]
1580,Enasidenib,[Drug]
1581,ACVR1,[Gene]
1582,ACVR1:Gain-of-Function,[Variant]
1583,ACVR1:G328V,[Variant]
1584,"Diffuse Midline Glioma, H3 K27M-mutant",[Disease]
1585,RET:RET FUSIONS,[Variant]
1586,"Avelumab,Nivolumab,Pembrolizumab,Durvalumab,Atezolizumab",[Drug]
1587,"Erlotinib,Dacomitinib",[Drug]
1588,FGFR3:FGFR3 FUSIONS,[Variant]
1589,Adrenal Carcinoma,[Disease]
1590,"Pemetrexed,Docetaxel,Trametinib",[Drug]
1591,"Nivolumab,Atezolizumab",[Drug]
1592,Immune Checkpoint Inhibitor,[Drug]
1593,"Selumetinib,Cetuximab",[Drug]
1594,"Erlotinib,Selumetinib",[Drug]
1595,"Palbociclib,Binimetinib",[Drug]
1596,CHEK1,[Gene]
1597,CHEK1:OVEREXPRESSION,[Variant]
1598,"Cisplatin,Prexasertib,Olaparib",[Drug]
1599,TP53:G245S,[Variant]
1600,TP53:M237I,[Variant]
1601,TP53:R158H,[Variant]
1602,TP53:V157F,[Variant]
1603,TP53:R249S,[Variant]
1604,TP53:R280K,[Variant]
1605,TP53:R280T,[Variant]
1606,TP53:R158L,[Variant]
1607,VHL:E46* (c.136G>T),[Variant]
1608,VHL:E55* (c.163G>T),[Variant]
1609,VHL:Y98H (c.292T>C),[Variant]
1610,VHL:H115Q (c.345C>A),[Variant]
1611,VHL:F119L (c.357C>G),[Variant]
1612,VHL:A149T (c.445G>A),[Variant]
1613,VHL:T157I (c.470C>T),[Variant]
1614,VHL:R161Q (c.482G>A),[Variant]
1615,VHL:R167W (c.499C>T),[Variant]
1616,VHL:R167Q (c.500G>A),[Variant]
1617,VHL:L178P (c.533T>C),[Variant]
1618,VHL:V62fs (c.180del),[Variant]
1619,VHL:S65W (c.194C>G),[Variant]
1620,VHL:Q73* (c.217C>T),[Variant]
1621,VHL:F76del (c.224_226delTCT),[Variant]
1622,VHL:N78H (c.232A>C),[Variant]
1623,VHL:N78S (c.233A>G),[Variant]
1624,VHL:N78T (c.233A>C),[Variant]
1625,VHL:S80I (c.239G>T),[Variant]
1626,VHL:P86fs (c.254_255insC),[Variant]
1627,VHL:P86L (c.257C>T),[Variant]
1628,VHL:W88R (c.262T>A),[Variant]
1629,VHL:S111FS (c.331delA),[Variant]
1630,VHL:S111N (c.332G>A),[Variant]
1631,VHL:S111R (c.333C>G),[Variant]
1632,EGFR:Gain-of-function,[Variant]
1633,VHL:Y112* (c.336C>A),[Variant]
1634,VHL:W117C (c.351G>T),[Variant]
1635,VHL:L129Q (c.386insAGA),[Variant]
1636,VHL:L135* (c.404T>A),[Variant]
1637,VHL:N150fs (c.449del),[Variant]
1638,VHL:P154fs (c.462delA),[Variant]
1639,VHL:C162R (c.484T>C),[Variant]
1640,VHL:C162F (c.485G>T),[Variant]
1641,VHL:C162W (c.486C>G),[Variant]
1642,VHL:V166D (c.497T>A),[Variant]
1643,VHL:L184P (c.551T>C),[Variant]
1644,VHL:E186* (c.556G>T),[Variant]
1645,VHL:E186K (c.556G>A),[Variant]
1646,"Fluorouracil,Leucovorin,Trastuzumab",[Drug]
1647,VHL:A56fs (c.166_167insA),[Variant]
1648,VHL:S65L (c.194C>T),[Variant]
1649,VHL:C77fs (c.228dup),[Variant]
1650,VHL:R79P (c.236G>C),[Variant]
1651,VHL:S80R (c.240T>G),[Variant]
1652,VHL:L89P (c.266T>C),[Variant]
1653,VHL:G114C (c.340G>T),[Variant]
1654,VHL:L118P (c.353T>C),[Variant]
1655,VHL:N131fs (c.390_391del),[Variant]
1656,VHL:F136S (c.407T>C),[Variant]
1657,VHL:L153fs (c.457delC),[Variant]
1658,VHL:P154L (c.461C>T),[Variant]
1659,VHL:L158V (c.472C>G),[Variant]
1660,VHL:V170F (c.508G>T),[Variant]
1661,VHL:I180V (c.538A>G),[Variant]
1662,VHL:Q195* (c.583C>T),[Variant]
1663,"Docetaxel,Erlotinib",[Drug]
1664,VHL:V170D (c.509T>A),[Variant]
1665,POLE:P286R,[Variant]
1666,POLE:V411L,[Variant]
1667,POLE:S459F,[Variant]
1668,VHL:L116V (c.346C>G),[Variant]
1669,VHL:V166F (c.496G>T),[Variant]
1670,VHL:S65* (c.194C>A),[Variant]
1671,VHL:E70* (c.208G>T),[Variant]
1672,VHL:F76S (c.227T>C),[Variant]
1673,VHL:L101G (c.301_302delinsGG),[Variant]
1674,VHL:T105P (c.313A>C),[Variant]
1675,VHL:R107P (c.320G>C),[Variant]
1676,VHL:R113* (c.337C>T),[Variant]
1677,VHL:L118fs (c.352_353insA),[Variant]
1678,VHL:N131T (c.392A>C),[Variant]
1679,VHL:T133fs (c.397del),[Variant]
1680,VHL:D143fs (c.430delG),[Variant]
1681,VHL:R161* (c.481C>T),[Variant]
1682,VHL:Q164* (c.490C>T),[Variant]
1683,VHL:Y175D (c.523T>G),[Variant]
1684,VHL:V181fs (c.540_543del),[Variant]
1685,VHL:Y185* (c.555C>G),[Variant]
1686,VHL:Q96* (c.286C>T),[Variant]
1687,VHL:P86R (c.257C>G),[Variant]
1688,VHL:G144* (c.430G>T),[Variant]
1689,VHL:L188P (c.563T>C),[Variant]
1690,VHL:S111C (c.330_331delinsTT),[Variant]
1691,VHL:R64P (c.191G>C),[Variant]
1692,VHL:E189fs (c.565del),[Variant]
1693,VHL:Splicing alteration (c.340+1G>A),[Variant]
1694,VHL:G93S (c.277G>A),[Variant]
1695,VHL:I151T (c.452T>C),[Variant]
1696,VHL:L158P (c.473T>C),[Variant]
1697,VHL:S68P (c.202T>C),[Variant]
1698,VHL:Q132P (c.395A>C),[Variant]
1699,VHL:Q164R (c.491A>G),[Variant]
1700,VHL:E94* (c.280G>T),[Variant]
1701,VHL:P103FS (c.309_310delTG),[Variant]
1702,VHL:H115P (c.344A>C),[Variant]
1703,VHL:L128R (c.383T>G),[Variant]
1704,VHL:L169P (c.506T>C),[Variant]
1705,VHL:L178R (c.533T>G),[Variant]
1706,VHL:M54fs (c.161dup),[Variant]
1707,VHL:F91* (c.272_273delinsAA),[Variant]
1708,VHL:P59fs (c.176delC),[Variant]
1709,VHL:P86S (c.256C>T),[Variant]
1710,VHL:S65P (c.193T>C),[Variant]
1711,VHL:S72P (c.214T>C),[Variant]
1712,VHL:S72fs (c.214del),[Variant]
1713,VHL:T124fs (c.369del),[Variant]
1714,VHL:L135FS (c.404delT),[Variant]
1715,VHL:R176fs (c.526del),[Variant]
1716,VHL:R177fs (c.528del),[Variant]
1717,VHL:W88* (c.264G>A),[Variant]
1718,VHL:V155E (c.464T>A),[Variant]
1719,VHL:V170G (c.509T>G),[Variant]
1720,VHL:F76fs (c.223_224insT),[Variant]
1721,VHL:K196* (c.586A>T),[Variant]
1722,VHL:R120G (c.358A>G),[Variant]
1723,VHL:R167L (c.500G>T),[Variant]
1724,VHL:D126FS (c.375_376insC),[Variant]
1725,VHL:E160FS (c.479_480delAG),[Variant]
1726,VHL:H115Y (c.343C>T),[Variant]
1727,VHL:L153P (c.458T>C),[Variant]
1728,VHL:L184R (c.551T>G),[Variant]
1729,VHL:L188R (c.563T>G),[Variant]
1730,VHL:P138T (c.412C>A),[Variant]
1731,"Olaparib,Paclitaxel",[Drug]
1732,VHL:Y98C  (c.293A>G),[Variant]
1733,VHL:R69fs (c.204insG),[Variant]
1734,VHL:Splicing alteration (c.340+5G>C),[Variant]
1735,VHL:G144fs (c.432insG),[Variant]
1736,VHL:Q145* (c.433C>T),[Variant]
1737,VHL:N131K (c.393C>A),[Variant]
1738,VHL:T105fs (c.315insAC),[Variant]
1739,VHL:P71fs (c.211insT),[Variant]
1740,VHL:E52K (c.154G>A),[Variant]
1741,VHL:E70K (c.208G>A),[Variant]
1742,VHL:H115Q (c.345C>G),[Variant]
1743,VHL:H191FS (c.571delC),[Variant]
1744,VHL:L140fs (c.417_418delTC),[Variant]
1745,VHL:K159fs (c.473dup),[Variant]
1746,VHL:P154= (c.462A>C),[Variant]
1747,VHL:S80R (c.238A>C),[Variant]
1748,VHL:S80N (c.239G>A),[Variant]
1749,VHL:R60FS (c.179delG),[Variant]
1750,VHL:W88S (c.263G>C),[Variant]
1751,VHL:Y156D (c.466T>G),[Variant]
1752,VHL:Y156C (c.467A>G),[Variant]
1753,VHL:Y156* (c.468T>G),[Variant]
1754,VHL:Y175* (c.525C>G),[Variant]
1755,VHL:V130L (c.388G>C),[Variant]
1756,VHL:G114R (c.340G>C),[Variant]
1757,VHL:R177* (c.529A>T),[Variant]
1758,VHL:*214L (c.641G>T),[Variant]
1759,VHL:*214W (c.642A>G),[Variant]
1760,VHL:*214C (c.642A>T),[Variant]
1761,"Everolimus,Sunitinib",[Drug]
1762,VHL:Splicing alteration (c.464-1G>T),[Variant]
1763,"Cetuximab,Panitumumab",[Drug]
1764,Imatinib Mesylate,[Drug]
1765,PIK3CA:EXON 10 and EXON 21 MUTATIONS,[Variant]
1766,VHL:Splicing alteration (c.464-2A>T),[Variant]
1767,VHL:R161G (c.481C>G),[Variant]
1768,VHL:Splicing alteration (c.463+2T>C),[Variant]
1769,VHL:Splicing alteration (c.464-1G>A),[Variant]
1770,VHL:Q132* (c.394C>T),[Variant]
1771,VHL:C77_N78insL (c.230_231insTCT),[Variant]
1772,VHL:L129fs (c.384delT),[Variant]
1773,VHL:L178Q (c.533T>A),[Variant]
1774,VHL:P81S (c.241C>T),[Variant]
1775,VHL:S183* (c.548C>A),[Variant]
1776,VHL:Splicing alteration (c.463+1G>C),[Variant]
1777,VHL:V74G (c.221T>G),[Variant]
1778,VHL:H115R (c.344A>G),[Variant]
1779,VHL:R107G  (c.319C>G),[Variant]
1780,VHL:R161P (c.482G>C),[Variant]
1781,VHL:G93C (c.277G>T),[Variant]
1782,VHL:G93V (c.278G>T),[Variant]
1783,VHL:L188V (c.562C>G),[Variant]
1784,VHL:L198Q  (c.593T>A),[Variant]
1785,VHL:F136C (c.407T>G),[Variant]
1786,VHL:S65A (c.193T>G),[Variant]
1787,VHL:S68W (c.203C>G),[Variant]
1788,VHL:Y156N (c.466T>A),[Variant]
1789,VHL:P61fs (c.183insC),[Variant]
1790,VHL:V84L (c.250G>T),[Variant]
1791,VHL:L85P (c.254T>C),[Variant]
1792,VHL:G93R (c.277G>C),[Variant]
1793,VHL:R108dup (c.322_324dup),[Variant]
1794,VHL:D121G (c.362A>G),[Variant]
1795,VHL:V194fs (c.581_582del),[Variant]
1796,VHL:A149fs (c.449del14-nt),[Variant]
1797,VHL:3'UTR alteration (c.639+10C>G),[Variant]
1798,VHL:G114S (c.340G>A),[Variant]
1799,VHL:W117fs (c.349dup),[Variant]
1800,VHL:A122I (c.364_365GC>AT),[Variant]
1801,VHL:N150fs (c.445_458del),[Variant]
1802,VHL:I151M (c.453C>G),[Variant]
1803,VHL:Splicing alteration (c.464-2A>G),[Variant]
1804,VHL:L163H (c.488T>A),[Variant]
1805,VHL:Y112H (c.334T>C),[Variant]
1806,VHL:L128F (c.382C>T),[Variant]
1807,VHL:L129P (c.386T>C),[Variant]
1808,VHL:C162fs (c.483del),[Variant]
1809,VHL:Null (Partial deletion of Exons 2 & 3),[Variant]
1810,VHL:N78I (c.233A>T),[Variant]
1811,VHL:C162Y (c.485G>A),[Variant]
1812,VHL:W88FS (c.263_265delGGCinsTT),[Variant]
1813,VHL:K159fs (c.477_478insCA),[Variant]
1814,VHL:Q73FS (c.217delC),[Variant]
1815,VHL:A149fs (c.445delG),[Variant]
1816,JQ-1,[Drug]
1817,"Vinorelbine,Docetaxel,Gemcitabine",[Drug]
1818,DICER1,[Gene]
1819,DICER1:E1705K,[Variant]
1820,Malignant Sertoli-Leydig Cell Tumor,[Disease]
1821,DICER1:D1709N,[Variant]
1822,DICER1:E1813Q,[Variant]
1823,VHL:P146fs (c.437del),[Variant]
1824,VHL:W88R (c.262T>C),[Variant]
1825,VHL:H115fs (c.344del),[Variant]
1826,VHL:P102fs (c.305delC),[Variant]
1827,"Paclitaxel,Vinorelbine,Gemcitabine",[Drug]
1828,VHL:R82_V84del (c.243_251del),[Variant]
1829,VHL:P40fs (c.118ins),[Variant]
1830,VHL:T152fs (c.455insA),[Variant]
1831,VHL:T157fs (c.472ins),[Variant]
1832,VHL:L158fs (c.471dupT),[Variant]
1833,VHL:D92_Y98del (c.275_292del),[Variant]
1834,VHL:E160fs (c.477del),[Variant]
1835,VHL:V66del (c.197_220del),[Variant]
1836,ARID1A:UNDEREXPRESSION,[Variant]
1837,VHL:E94FS (c.279delC),[Variant]
1838,VHL:G114dup (c.342dupGGT),[Variant]
1839,VHL:S65FS (c.194delC),[Variant]
1840,VHL:Q73fs (c.214insGCCC),[Variant]
1841,VHL:Splicing alteration (c.341-2A>C),[Variant]
1842,VHL:G114fs (c.341delCGTTTCCAACAATTTCTCGGTGT),[Variant]
1843,VHL:H125fs (c.374insA),[Variant]
1844,VHL:K159fs (c.474_476delGAAinsC),[Variant]
1845,VHL:Y175* (c.525delC),[Variant]
1846,VHL:L188fs (c.562delC),[Variant]
1847,VHL:K196fs (c.584_585delAG),[Variant]
1848,VHL:D197FS (c.589delG),[Variant]
1849,VHL:T202fs (c.606insA),[Variant]
1850,VHL:R113FS (c.337delC),[Variant]
1851,VHL:A56fs (c.166dup),[Variant]
1852,VHL:P61FS (c.182_185delCCGT),[Variant]
1853,VHL:Splicing alteration (c.464-1G>C),[Variant]
1854,VHL:EXON 3 DELETION,[Variant]
1855,VHL:R161= (c.481C>A),[Variant]
1856,VHL:I151F (c.451A>T),[Variant]
1857,VHL:W88* (c.263G>A),[Variant]
1858,VHL:3'UTR alteration (c.642+70C>A),[Variant]
1859,VHL:Y98FS (c.291delC),[Variant]
1860,VHL:N150S (c.449A>G),[Variant]
1861,NRG1:SLC3A2-NRG1,[Variant]
1862,RAD50,[Gene]
1863,RAD50:L1237F,[Variant]
1864,Ureter Small Cell Carcinoma,[Disease]
1865,"Irinotecan,Checkpoint Kinase Inhibitor AZD7762",[Drug]
1866,BTK:MUTATION,[Variant]
1867,PLCG2,[Gene]
1868,PLCG2:MUTATION,[Variant]
1869,Rilotumumab,[Drug]
1870,NRG1:ATP1B1-NRG1,[Variant]
1871,NRG1:SDC4-NRG1,[Variant]
1872,VHL:R82P (c.245G>C),[Variant]
1873,VHL:R177ins (c.531insCTGAGAGTAAAGCCTGAA),[Variant]
1874,DICER1:D1709G,[Variant]
1875,DICER1:D1709E,[Variant]
1876,Glandular Pattern Ovarian Yolk Sac Tumor,[Disease]
1877,"Dabrafenib,Trametinib Dimethyl Sulfoxide",[Drug]
1878,"Vemurafenib,Panitumumab,Irinotecan",[Drug]
1879,EGFR:EGFR-RAD51,[Variant]
1880,FGFR2:FGFR2 mutations,[Variant]
1881,"Oxaliplatin,Cisplatin",[Drug]
1882,"Hyperthermic Intraperitoneal Chemotherapy,Cytoreductive Surgery",[Drug]
1883,BAP1:ALTERNATIVE TRANSCRIPT (ATI),[Variant]
1884,"Apitolisib,Olaparib",[Drug]
1885,"Gemcitabine,Cisplatin,Veliparib",[Drug]
1886,"Gemcitabine,Veliparib,Cisplatin",[Drug]
1887,Veliparib,[Drug]
1888,Iniparib,[Drug]
1889,ALK:STRN-ALK,[Variant]
1890,BARD1,[Gene]
1891,BARD1:LOSS-OF-FUNCTION,[Variant]
1892,Thyroid Gland Anaplastic Carcinoma,[Disease]
1893,"Trastuzumab,Capecitabine",[Drug]
1894,"Gemcitabine,Trastuzumab",[Drug]
1895,Solid Tumor,[Disease]
1896,"Paclitaxel,Carboplatin,Buparlisib",[Drug]
1897,"Vemurafenib,Pertuzumab",[Drug]
1898,Laryngeal Squamous Cell Carcinoma,[Disease]
1899,BRAF:G464V,[Variant]
1900,BRAF:G469A,[Variant]
1901,BRAF:G496A,[Variant]
1902,BRAF:N581S,[Variant]
1903,BRAF:G466V,[Variant]
1904,BRAF:G606E,[Variant]
1905,BRAF:P731T,[Variant]
1906,BRAF:intron 9 rearrangement,[Variant]
1907,BRAF:intron 10 rearrangement,[Variant]
1908,BRAF:MACF1-BRAF,[Variant]
1909,BRAF:WASFL-BRAF,[Variant]
1910,BRAF:CUX1-BRAF,[Variant]
1911,"Trastuzumab,Pertuzumab",[Drug]
1912,"Pertuzumab,Trastuzumab",[Drug]
1913,Biliary Tract Cancer,[Disease]
1914,Uterine Cancer,[Disease]
1915,ASS1,[Gene]
1916,ASS1:LOSS,[Variant]
1917,"Pegargiminase,Chloroquine",[Drug]
1918,BCL2:MUTATION,[Variant]
1919,RASA1,[Gene]
1920,RASA1:LOSS-OF-FUNCTION,[Variant]
1921,TLK2,[Gene]
1922,TLK2:AMPLIFICATION,[Variant]
1923,"Go6983,GF109203X",[Drug]
1924,U0126,[Drug]
1925,BRAF:G469E,[Variant]
1926,Ovarian Sex-cord Stromal Tumor,[Disease]
1927,Vagina Sarcoma,[Disease]
1928,Epithelioid Inflammatory Myofibroblastic Sarcoma,[Disease]
1929,"Vemurafenib,Cobimetinib",[Drug]
1930,"Encorafenib,Cetuximab",[Drug]
1931,"Alpelisib,Encorafenib,Cetuximab",[Drug]
1932,Meloxicam,[Drug]
1933,VHL:R82_V84del (c.244_252del),[Variant]
1934,VHL:L188Q (c.563T>A),[Variant]
1935,VHL:A56_P59del (c.166_178del),[Variant]
1936,ACVR1:G328E,[Variant]
1937,NRG1:NRG1 FUSIONS,[Variant]
1938,Mucinous Adenocarcinoma,[Disease]
1939,NTRK2,[Gene]
1940,NTRK2:STRN-NTRK2,[Variant]
1941,Congenital Fibrosarcoma,[Disease]
1942,NTRK1:LMNA-NTRK1,[Variant]
1943,NTRK1:TPM3-NTRK1,[Variant]
1944,NTRK1:PDE4DIP-NTRK1,[Variant]
1945,VHL:G144E (c.431G>A),[Variant]
1946,Adrenal Gland Pheochromocytoma,[Disease]
1947,VHL:Splicing alteration (c.463+8C>T),[Variant]
1948,VHL:G104A (c.311G>C),[Variant]
1949,VHL:F91L (c.273C>G),[Variant]
1950,VHL:W88fs (c.261dup),[Variant]
1951,"Panitumumab,Dabrafenib,Trametinib",[Drug]
1952,"Panitumumab,Trametinib",[Drug]
1953,Salivary Gland Cancer,[Disease]
1954,"Paclitaxel,Trastuzumab",[Drug]
1955,"Zoledronic Acid,Trastuzumab,Capecitabine",[Drug]
1956,ERBB2:T798I,[Variant]
1957,EGFR:R705K,[Variant]
1958,EGFR:RARE EGRF MUT,[Variant]
1959,ABL1:BCR-ABL T315A,[Variant]
1960,"Fluorouracil,Epirubicin,Cyclophosphamide,Paclitaxel,Doxorubicin",[Drug]
1961,"Dasatinib,Nilotinib,Imatinib Mesylate",[Drug]
1962,ABL1:BCR-ABL L248R,[Variant]
1963,"Dasatinib,Imatinib Mesylate",[Drug]
1964,ABL1:BCR-ABL F317I,[Variant]
1965,ABL1:BCR-ABL F317S,[Variant]
1966,ABL1:BCR-ABL F317C,[Variant]
1967,AKT1:OVEREXPRESSION,[Variant]
1968,BRAF:V600E/K and AMPLIFICATION,[Variant]
1969,PIK3R2:OVEREXPRESSION,[Variant]
1970,PREX2,[Gene]
1971,PREX2:R172I,[Variant]
1972,"Imatinib Mesylate,Dasatinib,Nilotinib",[Drug]
1973,VHL:3p26.3-25.3 11Mb del,[Variant]
1974,ABL1:BCR-ABL E459K,[Variant]
1975,ABL1:TKD MUTATION,[Variant]
1976,KRAS:G13V,[Variant]
1977,VHL:c.128-?_250+?,[Variant]
1978,ABL1:P-Loop Mutation,[Variant]
1979,ABL1:Non-P-Loop Mutation,[Variant]
1980,CSF3R:T618I,[Variant]
1981,CALR:MUTATION,[Variant]
1982,Essential Thrombocythemia,[Disease]
1983,NTRK1:NTRK1-TRIM63,[Variant]
1984,NTRK1:NTRK1-DDR2,[Variant]
1985,NTRK1:NTRK1-GON4L,[Variant]
1986,NTRK2:ETV6-NTRK2,[Variant]
1987,BRAF:D594K,[Variant]
1988,"Atezolizumab,Pembrolizumab,Nivolumab",[Drug]
1989,SDHB,[Gene]
1990,SDHB:p.193_196dupSTSC (c.577_588dupAGCACCAGCTGC),[Variant]
1991,Paraganglioma,[Disease]
1992,H3-3A,[Gene]
1993,H3-3A:K27M,[Variant]
1994,H3-3B,[Gene]
1995,H3-3B:K36M,[Variant]
1996,Chondroblastoma,[Disease]
1997,H3-3A:G34W,[Variant]
1998,Bone Giant Cell Tumor,[Disease]
1999,Breast Secretory Carcinoma,[Disease]
2000,VHL:c.?213? ?_463 ?del,[Variant]
2001,VHL:V87fs (c.259_260insA),[Variant]
2002,VHL:c.341-59_341-14del,[Variant]
2003,VHL:V166A (c.497T>C),[Variant]
2004,VHL:REARRANGEMENT,[Variant]
2005,VHL:V66Gfs*89 (c.197_209del),[Variant]
2006,VHL:R79_S80del (c.236_241delGCAGTC),[Variant]
2007,VHL:P86A (c.256C>G),[Variant]
2008,VHL:D92G (c.275A>G),[Variant]
2009,VHL:V155G (c.464T>G),[Variant]
2010,VHL:Null (Complete deletion),[Variant]
2011,VHL:S111C (c.331A>T),[Variant]
2012,VHL:G114Vfs*45 (c.339delA),[Variant]
2013,VHL:Splicing alteration (c.464-2G>A),[Variant]
2014,VHL:Q164L (c.491A>T),[Variant]
2015,VHL:R167P (c.500G>C),[Variant]
2016,VHL:Y175* (c.525C>A),[Variant]
2017,VHL:L178P (c.532C>T),[Variant]
2018,VHL:EXON 2 DELETION,[Variant]
2019,VHL:EXON 2-3 DELETION,[Variant]
2020,PRKCB,[Gene]
2021,PRKCB:D427N,[Variant]
2022,Adult T-cell Leukemia,[Disease]
2023,VHL:*214G (c.640T>G),[Variant]
2024,VHL:*214C (c.641_642insC),[Variant]
2025,Childhood B-cell Acute Lymphoblastic Leukemia,[Disease]
2026,HRAS:Q61,[Variant]
2027,ABL1:ETV6-ABL1,[Variant]
2028,JAK2:GOLGA5-JAK2,[Variant]
2029,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like",[Disease]
2030,NCOA2,[Gene]
2031,NCOA2:HEY1-NCOA2,[Variant]
2032,Mesenchymal Chondrosarcoma,[Disease]
2033,FOXO1,[Gene]
2034,FOXO1:PAX3-FOXO1,[Variant]
2035,Alveolar Rhabdomyosarcoma,[Disease]
2036,FOXO1:PAX7-FOXO1,[Variant]
2037,PARP1,[Gene]
2038,PARP1:OVEREXPRESSION,[Variant]
2039,Birabresib,[Drug]
2040,JAK2:JAK2 F694L,[Variant]
2041,Selpercatinib,[Drug]
2042,EGFR:V441F,[Variant]
2043,"Dasatinib,Imatinib",[Drug]
2044,VHL:G104V (c.311G>T),[Variant]
2045,Pilocytic Astrocytoma,[Disease]
2046,SMARCA4:LOSS,[Variant]
2047,"Abemaciclib,Palbociclib",[Drug]
2048,Lymphoma,[Disease]
2049,TP53:C238Y,[Variant]
2050,H3-3A:MUTATION,[Variant]
2051,Pediatric Low-grade Glioma,[Disease]
2052,ATRX:DELETION,[Variant]
2053,CDKN2A:DELETION,[Variant]
2054,MYB,[Gene]
2055,MYB:AMPLIFICATION,[Variant]
2056,"Everolimus,Trametinib",[Drug]
2057,FGFR1:INTERNAL DUPLICATION,[Variant]
2058,CRLF2,[Gene]
2059,CRLF2:CRLF2-IGH,[Variant]
2060,Li-Fraumeni Syndrome,[Disease]
2061,ABL1:SNX2-ABL1,[Variant]
2062,ABL1:ABL1-RCSD,[Variant]
2063,ABL1:ABL1-RCSD1,[Variant]
2064,ABL2,[Gene]
2065,ABL2:ABL2 fusions,[Variant]
2066,JAK2:SSBP2-JAK2,[Variant]
2067,"Binimetinib,Cetuximab,Encorafenib",[Drug]
2068,Tepotinib,[Drug]
2069,ROS1:FUSION,[Variant]
2070,Gilteritinib,[Drug]
2071,"Binimetinib,Encorafenib",[Drug]
2072,KIT:V555_V559DEL,[Variant]
2073,KIT:K550_K559DEL,[Variant]
2074,ABL1:FOXP1-ABL1,[Variant]
2075,CDKN2A:MUTATION,[Variant]
2076,"Alpelisib,Fulvestrant",[Drug]
2077,Icotinib,[Drug]
2078,"Fulvestrant,Alpelisib",[Drug]
2079,"Sorafenib,Sunitinib",[Drug]
2080,FGFR1:FGFR1OP2-FGFR1,[Variant]
2081,IKZF1:IKZF1 deletion and mutation,[Variant]
2082,"Ponatinib,Imatinib",[Drug]
2083,"Sunitinib,Ponatinib",[Drug]
2084,"Sorafenib,Vemurafenib",[Drug]
2085,KIT:A829P,[Variant]
2086,"Sunitinib,Imatinib",[Drug]
2087,Spindle Cell Sarcoma,[Disease]
2088,"Doxorubicin,Methotrexate",[Drug]
2089,NFE2L2,[Gene]
2090,NFE2L2:MUTATION,[Variant]
2091,Sapanisertib,[Drug]
2092,Vistusertib,[Drug]
2093,Agerafenib,[Drug]
2094,ALK:CAD-ALK,[Variant]
2095,ROS1:GOPC-ROS1,[Variant]
2096,NRG1:APP-NRG1,[Variant]
2097,MET:R1004G,[Variant]
2098,TP53:R282W,[Variant]
2099,"Irinotecan,Panitumumab",[Drug]
2100,Urinary Bladder Cancer,[Disease]
2101,Glioma,[Disease]
2102,Akt/ERK Inhibitor ONC201,[Drug]
2103,BRAF:A728V,[Variant]
2104,BRAF Inhibitor,[Drug]
2105,"BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor",[Drug]
2106,BRAF:V600_K601>E,[Variant]
2107,"Mitogen-Activated Protein Kinase Kinase Inhibitor,BRAF Inhibitor",[Drug]
2108,BRAF:G469,[Variant]
2109,BRAF:A598V,[Variant]
2110,FGF19,[Gene]
2111,FGF19:EXPRESSION,[Variant]
2112,Fisogatinib,[Drug]
2113,Trastuzumab Deruxtecan,[Drug]
2114,JAK2:ATF7IP-JAK2,[Variant]
2115,JAK2:EBF1-JAK2,[Variant]
2116,JAK2:PPFIBP1-JAK2,[Variant]
2117,JAK2:STRN3-JAK2,[Variant]
2118,JAK2:TPR-JAK2,[Variant]
2119,JAK2:ETV6-JAK2,[Variant]
2120,JAK2:BCR-JAK2,[Variant]
2121,JAK2:PAX5-JAK2,[Variant]
2122,JAK2:TERF2-JAK2,[Variant]
2123,JAK2:ZNF274-JAK2,[Variant]
2124,JAK2:RFX3-JAK2,[Variant]
2125,BRCA2:K3226*,[Variant]
2126,"Temozolomide,Olaparib",[Drug]
2127,Chondrosarcoma,[Disease]
2128,BRAF:N486_P490del,[Variant]
2129,BRAF:NRF1-BRAF,[Variant]
2130,ABL1:BCR-ABL T315V,[Variant]
2131,ABL1:BCR-ABL E292L,[Variant]
2132,ABL1:BCR-ABL F317R,[Variant]
2133,ABL1:BCR-ABL L248R F359I,[Variant]
2134,"Axitinib,Ponatinib",[Drug]
2135,"Nilotinib,Imatinib,Dasatinib",[Drug]
2136,"Imatinib,Dasatinib,Nilotinib",[Drug]
2137,ABL1:BCR-ABL E255K V299L,[Variant]
2138,"Ponatinib,Dasatinib",[Drug]
2139,CTNNB1:exon 3 mutation,[Variant]
2140,DPYD:EXON 11-19 DELETION,[Variant]
2141,"Fluorouracil,Leucovorin",[Drug]
2142,MET:MET-ATXN7L1,[Variant]
2143,Histiocytic And Dendritic Cell Cancer,[Disease]
2144,"Dexamethasone,Ribociclib",[Drug]
2145,Glioblastoma Proneural Subtype,[Disease]
2146,CDK6:EXPRESSION,[Variant]
2147,Adenosquamous Lung Carcinoma,[Disease]
2148,Childhood Acute Lymphocytic Leukemia,[Disease]
2149,NT5C2:R238W,[Variant]
2150,NT5C2:S445F,[Variant]
2151,"Thioguanine,Mercaptopurine",[Drug]
2152,"Cytarabine,Doxorubicin,Prednisolone,Gemcitabine",[Drug]
2153,"Doxorubicin,Gemcitabine,Prednisolone,Cytarabine",[Drug]
2154,"Gemcitabine,Prednisolone,Cytarabine,Doxorubicin",[Drug]
2155,NT5C2:NT5C2 MUTATION,[Variant]
2156,PRPS1,[Gene]
2157,PRPS1:PRPS1 MUTATION,[Variant]
2158,PRPS1:A190T,[Variant]
2159,VHL:106insR (c.316insGCC),[Variant]
2160,PRPS1:T303S,[Variant]
2161,PRPS1:L191F,[Variant]
2162,PRPS1:D183E,[Variant]
2163,PRPS1:K176N,[Variant]
2164,PRPS1:N144S,[Variant]
2165,PRPS1:S103I,[Variant]
2166,PRPS1:S103N,[Variant]
2167,PRPS1:S103T,[Variant]
2168,"Mercaptopurine,Lometrexol",[Drug]
2169,PRPS1:D139G,[Variant]
2170,PRPS1:C77S,[Variant]
2171,PRPS1:I72V,[Variant]
2172,PRPS1:V53A,[Variant]
2173,PRPS1:A87T,[Variant]
2174,PRPS1:M115T,[Variant]
2175,"Asparaginase,Daunorubicin,Methotrexate",[Drug]
2176,"Asparaginase,Cytarabine,Methotrexate,Daunorubicin",[Drug]
2177,"Methotrexate,Cytarabine,Daunorubicin,Asparaginase",[Drug]
2178,"Methotrexate,Cytarabine,Asparaginase,Daunorubicin",[Drug]
2179,"Methotrexate,Asparaginase,Daunorubicin",[Drug]
2180,ABL1:BCR-ABL E450Q,[Variant]
2181,ABL1:BCR-ABL M244V and L364I,[Variant]
2182,ABL1:BCR-ABL N146S,[Variant]
2183,ABL1:BCR-ABL V298I,[Variant]
2184,ABL1:BCR-ABL S438C,[Variant]
2185,ABL1:BCR-ABL M388L,[Variant]
2186,IL6,[Gene]
2187,IL6:OVEREXPRESSION,[Variant]
2188,Rhabdomyosarcoma,[Disease]
2189,Bazedoxifene,[Drug]
2190,CHEK2:R474C c.1420C>T,[Variant]
2191,CTNNB1:exon 3 mutations,[Variant]
2192,PDGFRA:OVEREXPRESSION,[Variant]
2193,PDGFRA:BCR-PDGFRA,[Variant]
2194,B-cell Acute Lymphoblastic Leukemia,[Disease]
2195,PDGFB,[Gene]
2196,PDGFB:COL1A1-PDGFB,[Variant]
2197,PDGFRB:OVEREXPRESSION,[Variant]
2198,JAK2:SMU1-JAK2,[Variant]
2199,JAK2:OFD1-JAK2,[Variant]
2200,JAK2:SNX29-JAK2,[Variant]
2201,JAK2:ZNF430-JAK2,[Variant]
2202,PIK3CA:V955I,[Variant]
2203,ABL1:Double Ph,[Variant]
2204,FLT3:D835Y,[Variant]
2205,Arsenic Trioxide,[Drug]
2206,MYOD1,[Gene]
2207,MYOD1:L122R,[Variant]
2208,Spindle Cell Rhabdomyosarcoma,[Disease]
2209,"Imatinib,Chemotherapy",[Drug]
2210,FLT3:Y842C,[Variant]
2211,FLT3/ABL/Aurora Kinase Inhibitor KW-2449,[Drug]
2212,FLT3:F691L,[Variant]
2213,FLT3:D835I,[Variant]
2214,"Vemurafenib,Akt Inhibitor MK2206",[Drug]
2215,BCL2:F104I,[Variant]
2216,Venetoclax,[Drug]
2217,"Vemurafenib,Erlotinib",[Drug]
2218,ABL1:BCR-ABL Y253F,[Variant]
2219,NTRK2:KANK1-NTRK2,[Variant]
2220,"Lapatinib,Capecitabine",[Drug]
2221,Ovary Serous Adenocarcinoma,[Disease]
2222,KRAS:Wildtype,[Variant]
2223,BCL2:G101V,[Variant]
2224,Thanatophoric Dysplasia,[Disease]
2225,SMARCB1:LOSS,[Variant]
2226,Atypical Teratoid Rhabdoid Tumor,[Disease]
2227,ATRX:Loss-of-function,[Variant]
2228,"Etoposide,Larotrectinib,Methotrexate",[Drug]
2229,Renal Wilms' Tumor,[Disease]
2230,ERBB2:Oncogenic Mutations,[Variant]
2231,AZD5363,[Drug]
2232,PTCH1:Truncating Mutations,[Variant]
2233,"Skin Cancer, Non-Melanoma",[Disease]
2234,EGFR:Kinase Domain Duplication,[Variant]
2235,Non-Small Cell Lung Cancer,[Disease]
2236,Embryonal Tumor,[Disease]
2237,IDH1:Oncogenic Mutations,[Variant]
2238,EGFR:Exon 20 insertion,[Variant]
2239,Poziotinib,[Drug]
2240,MAP2K2,[Gene]
2241,MAP2K2:Oncogenic Mutations,[Variant]
2242,Histiocytosis,[Disease]
2243,NRAS:Oncogenic Mutations,[Variant]
2244,BRAF:Oncogenic Mutations,[Variant]
2245,Binimetinib + Ribociclib,[Drug]
2246,ESR1:Oncogenic Mutations,[Variant]
2247,"AZD9496, Fulvestrant",[Drug]
2248,Thyroid Cancer,[Disease]
2249,Selumetinib + Iodine I 131-6-Beta-Iodomethyl-19-Norcholesterol,[Drug]
2250,KRAS:Oncogenic Mutations,[Variant]
2251,MAP2K1:Oncogenic Mutations,[Variant]
2252,"Trametinib, Cobimetinib",[Drug]
2253,"Cobimetinib, Trametinib",[Drug]
2254,FGFR3:Fusions,[Variant]
2255,Bladder Cancer,[Disease]
2256,"BGJ398, Debio1347, AZD4547",[Drug]
2257,Low-Grade Serous Ovarian Cancer,[Disease]
2258,"FGFR3:G380R, K650, S371C",[Variant]
2259,"AZD4547, BGJ398, Debio1347, Erdafitinib",[Drug]
2260,PIK3CA:Oncogenic Mutations,[Variant]
2261,GDC-0077,[Drug]
2262,Copanlisib + Fulvestrant,[Drug]
2263,"FGFR3:G370C, R248C, S249C, Y373C",[Variant]
2264,"Debio1347, BGJ398, AZD4547",[Drug]
2265,ABL1:BCR-ABL1 Fusion,[Variant]
2266,Chronic Myelogenous Leukemia,[Disease]
2267,Asciminib,[Drug]
2268,AMG-510,[Drug]
2269,JAK2:PCM1-JAK2 Fusion,[Variant]
2270,"Chronic Eosinophilic Leukemia, NOS",[Disease]
2271,HRAS:Oncogenic Mutations,[Variant]
2272,Head and Neck Squamous Cell Carcinoma,[Disease]
2273,Tipifarnib,[Drug]
2274,RET:Oncogenic Mutations,[Variant]
2275,Medullary Thyroid Cancer,[Disease]
2276,Pralsetinib,[Drug]
2277,BRAF:L597,[Variant]
2278,"MTOR:L1460P, L2209V, L2427Q",[Variant]
2279,FGFR2:Fusions,[Variant]
2280,"BGJ398, AZD4547, Debio1347",[Drug]
2281,BRAF:K601,[Variant]
2282,"MTOR:E2014K, E2419K",[Variant]
2283,KIT:D816,[Variant]
2284,Mastocytosis,[Disease]
2285,Avapritinib,[Drug]
2286,"AZD4547, BGJ398, Erdafitinib, Debio1347",[Drug]
2287,MTOR:Q2223K,[Variant]
2288,EGFR:E709_T710delinsD,[Variant]
2289,"MET:D1010, Exon 14 deletion, Exon 14 splice mutation, Y1003",[Variant]
2290,FLT3:Internal tandem duplication,[Variant]
2291,MDM2:Amplification,[Variant]
2292,RO5045337,[Drug]
2293,Milademetan Tosylate,[Drug]
2294,EGFR:Exon 19 insertion,[Variant]
2295,ERCC2:Oncogenic Mutations,[Variant]
2296,FGFR1:Amplification,[Variant]
2297,BRCA2:Oncogenic Mutations,[Variant]
2298,RAF1:Oncogenic Mutations,[Variant]
2299,ARAF:Oncogenic Mutations,[Variant]
2300,BRCA1:Oncogenic Mutations,[Variant]
2301,BRAF:Fusions,[Variant]
2302,Encorafenib + Panitumumab,[Drug]
2303,PDGFRA:Oncogenic Mutations,[Variant]
2304,"KIT:A829P, C809G, D816, D820, N822, Y823D",[Variant]
2305,RET:Fusions,[Variant]
2306,"ABL1:E255K, E255V, F317C, F317I, F317L, F317V, F359C, F359I, F359V, T315A, Y253H",[Variant]
2307,B-Lymphoblastic Leukemia/Lymphoma,[Disease]
2308,Ripretinib,[Drug]
2309,"ABL1:E255K, E255V, F359C, F359I, F359V, Y253H",[Variant]
2310,"ABL1:F317C, F317I, F317L, F317V, T315A, V299L",[Variant]
2311,ERBB2:Amplification,[Variant]
2312,Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma,[Disease]
2313,Carboplatin-Taxol Regimen + Trastuzumab,[Drug]
2314,"Vemurafenib + Cobimetinib, Dabrafenib + Trametinib",[Drug]
2315,Trastuzumab + Pertuzumab,[Drug]
2316,MET:Amplification,[Variant]
2317,Lapatinib + Trastuzumab,[Drug]
2318,Pleomorphic Xanthoastrocytoma,[Disease]
2319,"Dabrafenib + Trametinib, Vemurafenib + Cobimetinib",[Drug]
2320,Ganglioglioma,[Disease]
2321,KIT:Oncogenic Mutations,[Variant]
2322,Thymic Tumor,[Disease]
2323,CDK4:Amplification,[Variant]
2324,Dedifferentiated Liposarcoma,[Disease]
2325,"Palbociclib, Abemaciclib",[Drug]
2326,Well-Differentiated Liposarcoma,[Disease]
2327,"Abemaciclib, Palbociclib",[Drug]
2328,Encorafenib + Binimetinib,[Drug]
2329,ALK:Fusions,[Variant]
2330,Dabrafenib + Trametinib,[Drug]
2331,Vemurafenib + Cobimetinib,[Drug]
2332,Anaplastic Thyroid Cancer,[Disease]
2333,Ado-Trastuzumab Emtansine,[Drug]
2334,BRIP1,[Gene]
2335,BRIP1:Oncogenic Mutations,[Variant]
2336,"KIT:A502_Y503dup, K509I, N505I, S476I, S501_A502dup",[Variant]
2337,"KIT:D572A, D572_P573dup, D579_H580insFNPTQLPYD, D579_H580insLPCD, D579del, E554_I571del, E554_K558del, E554_V559del, Exon 11 deletion, I563_L576del, K550_K558del, K550_V555delinsI, K550_W557del, K558N, K558_E562del, K558_V559del, K558_V560del, K558delinsNP, L576P, L576del, M552_K558del, M552_W557del, N564_Y578del, P551_E554del, P551_M552del, P551_V555del, P551_W557delinsL, P573Q, P573_D579del, P577_D579del, P577_R588dup, P577_W582delinsPYD, Q556_K558del, Q575_L576dup, Q575_P585dup, T574_R588delinsL, T574insTQLPYD, V555_L576del, V555_V559del, V559A, V559C, V559D, V559F, V559G, V559I, V559_G565del, V559_V560del, V559del, V560D, V560E, V560G, V560del, V569_L576del, W557C, W557G, W557R, W557_K558del, W557_V559delinsC, W557_V560del, Y553_K558del, Y553_Q556del, Y568_L576delinsVN, Y578C, Y578_D579dup, Y578_D579insEQQLPY",[Variant]
2338,FANCL,[Gene]
2339,FANCL:Oncogenic Mutations,[Variant]
2340,PDGFB:COL1A1-PDGFB Fusion,[Variant]
2341,NF1:Oncogenic Mutations,[Variant]
2342,Neurofibroma,[Disease]
2343,NTRK2:Fusions,[Variant]
2344,All Solid Tumors,[Disease]
2345,"EGFR:Exon 19 deletion, L858R",[Variant]
2346,"FLT3:D835, I836, Internal tandem duplication",[Variant]
2347,NTRK3:Fusions,[Variant]
2348,Niraparib,[Drug]
2349,Peritoneal Serous Carcinoma,[Disease]
2350,RAD51B,[Gene]
2351,RAD51B:Oncogenic Mutations,[Variant]
2352,"Prostate Cancer, NOS",[Disease]
2353,CDK12:Oncogenic Mutations,[Variant]
2354,ALK:Oncogenic Mutations,[Variant]
2355,RAD51C,[Gene]
2356,RAD51C:Oncogenic Mutations,[Variant]
2357,ATM:Oncogenic Mutations,[Variant]
2358,Encorafenib + Cetuximab,[Drug]
2359,Pertuzumab + Trastuzumab,[Drug]
2360,Trastuzumab + Lapatinib,[Drug]
2361,BARD1:Oncogenic Mutations,[Variant]
2362,Capecitabine + Trastuzumab + Tucatinib,[Drug]
2363,Esophagogastric Cancer,[Disease]
2364,RAD51D:Oncogenic Mutations,[Variant]
2365,SMARCB1:Deletion,[Variant]
2366,Epithelioid Sarcoma,[Disease]
2367,RAD54L,[Gene]
2368,RAD54L:Oncogenic Mutations,[Variant]
2369,Erdheim-Chester Disease,[Disease]
2370,FLT3:Oncogenic Mutations,[Variant]
2371,Midostaurin + High Dose Chemotherapy,[Drug]
2372,Vemurafenib + Atezolizumab + Cobimetinib,[Drug]
2373,Other Biomarkers,[Gene]
2374,Other Biomarkers:Microsatellite Instability-High,[Variant]
2375,Ipilimumab + Nivolumab,[Drug]
2376,Fulvestrant + Alpelisib,[Drug]
2377,Other Biomarkers:Tumor Mutational Burden-High,[Variant]
2378,"BRAF:V600E, V600K",[Variant]
2379,TSC1:Oncogenic Mutations,[Variant]
2380,CNS Cancer,[Disease]
2381,CHEK1:Oncogenic Mutations,[Variant]
2382,PDGFRA:FIP1L1-PDGFRA Fusion,[Variant]
2383,PDGFRA:Fusions,[Variant]
2384,Myelodysplastic/Myeloproliferative Neoplasms,[Disease]
2385,Pemigatinib,[Drug]
2386,TSC2:Oncogenic Mutations,[Variant]
2387,IDH2:Oncogenic Mutations,[Variant]
2388,"PDGFRA:D842V, D842Y, D842_H845del, D842_H845insV",[Variant]
2389,"EZH2:A682G, A692V, Y646C, Y646F, Y646H, Y646N, Y646S",[Variant]
2390,PALB2:Oncogenic Mutations,[Variant]
2391,CHEK2:Oncogenic Mutations,[Variant]
2392,ABL1:T315I,[Variant]
2393,NTRK1:Fusions,[Variant]
2394,ROS1:Fusions,[Variant]
2395,PDGFRB:Fusions,[Variant]
2396,"Gefitinib, Afatinib, Erlotinib",[Drug]
2397,"Bosutinib, Nilotinib, Imatinib, Dasatinib",[Drug]
2398,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,[Disease]
2399,"Erlotinib, Afatinib, Gefitinib",[Drug]
2400,"Cetuximab, Panitumumab",[Drug]
2401,"Panitumumab, Cetuximab",[Drug]
2402,"Bosutinib, Dasatinib, Imatinib, Nilotinib",[Drug]
2403,U2AF1:Oncogenic Mutations,[Variant]
2404,H3B-8800,[Drug]
2405,ZRSR2,[Gene]
2406,ZRSR2:Oncogenic Mutations,[Variant]
2407,Myelodysplastic Syndromes,[Disease]
2408,FLI1:EWSR1-FLI1 Fusion,[Variant]
2409,TK216,[Drug]
2410,Ewing Sarcoma of Soft Tissue,[Disease]
2411,KDM6A,[Gene]
2412,KDM6A:Oncogenic Mutations,[Variant]
2413,MTOR:Oncogenic Mutations,[Variant]
2414,"Temsirolimus, Everolimus",[Drug]
2415,PLX8394,[Drug]
2416,SRSF2:Oncogenic Mutations,[Variant]
2417,CDKN2A:Oncogenic Mutations,[Variant]
2418,"Abemaciclib, Ribociclib, Palbociclib",[Drug]
2419,FGFR2:Oncogenic Mutations,[Variant]
2420,"BGJ398, Erdafitinib, AZD4547, Debio1347",[Drug]
2421,EGFR:Amplification,[Variant]
2422,CDK12:Truncating Mutations,[Variant]
2423,"Pembrolizumab, Cemiplimab, Nivolumab",[Drug]
2424,SMARCB1:Oncogenic Mutations,[Variant]
2425,All Liquid Tumors,[Disease]
2426,EGFR:L718V,[Variant]
2427,SF3B1:Oncogenic Mutations,[Variant]
2428,"Binimetinib, Trametinib, Cobimetinib",[Drug]
2429,"BRAF:G464, G469A, G469R, G469V",[Variant]
2430,MET:Fusions,[Variant]
2431,"EGFR:A289V, R108K, T263P",[Variant]
2432,FGFR1:Oncogenic Mutations,[Variant]
2433,"Debio1347, Erdafitinib, BGJ398, AZD4547",[Drug]
2434,PTEN:Oncogenic Mutations,[Variant]
2435,"AZD8186, GSK2636771",[Drug]
2436,FGFR3:Oncogenic Mutations,[Variant]
2437,"AZD4547, Erdafitinib, Debio1347, BGJ398",[Drug]
2438,MET:Y1230H,[Variant]
2439,"Crizotinib, Capmatinib",[Drug]
2440,ALK:C1156Y,[Variant]
2441,NTRK1:G595R,[Variant]
2442,ALK:G1202R,[Variant]
2443,ALK:G1269A,[Variant]
2444,KIT:D820,[Variant]
2445,"Erlotinib, Osimertinib, Gefitinib",[Drug]
2446,ALK:I1171N,[Variant]
2447,KIT:N822,[Variant]
2448,ALK:L1196M,[Variant]
2449,EGFR:C797G,[Variant]
2450,NTRK3:G623R,[Variant]
2451,"Capmatinib, Crizotinib, Cabozantinib",[Drug]
2630,JAK2,[Gene]
2809,JAK2:V617F,[Variant]
2810,Lymphoid Leukemia,[Disease]
2811,PDGFRA,[Gene]
2812,PDGFRA:D842V,[Variant]
2813,Gastrointestinal Stromal Tumor,[Disease]
2814,DNMT3A,[Gene]
2815,DNMT3A:R882,[Variant]
2816,Acute Myeloid Leukemia,[Disease]
2817,Chronic Myeloid Leukemia,[Disease]
2818,Bone Marrow Cancer,[Disease]
2819,KRAS,[Gene]
2820,KRAS:G12,[Variant]
2821,Acute Leukemia,[Disease]
2822,NRAS,[Gene]
2823,NRAS:Q61,[Variant]
2824,Melanoma,[Disease]
2825,Daunorubicin,[Drug]
2826,MAP2K1,[Gene]
2827,MAP2K1:P124S,[Variant]
2828,Selumetinib,[Drug]
2829,MAP2K1:Q56P,[Variant]
2830,Vemurafenib,[Drug]
2831,Imatinib,[Drug]
2832,ARAF,[Gene]
2833,ARAF:S214C,[Variant]
2834,Lung Non-small Cell Carcinoma,[Disease]
2835,Sorafenib,[Drug]
2836,Idarubicin,[Drug]
2837,Polycythemia Vera,[Disease]
2838,Fedratinib,[Drug]
2839,NRAS:G13D,[Variant]
2840,Tanespimycin,[Drug]
2841,NRAS:Q61L,[Variant]
2842,Temozolomide,[Drug]
2843,NRAS:Q61R,[Variant]
2844,KIT,[Gene]
2845,KIT:D816V,[Variant]
2846,NRAS:MUTATION,[Variant]
2847,Colorectal Cancer,[Disease]
2848,BRAF,[Gene]
2849,BRAF:V600,[Variant]
2850,ALK,[Gene]
2851,ALK:F1174L,[Variant]
2852,Inflammatory Myofibroblastic Tumor,[Disease]
2853,Crizotinib,[Drug]
2854,KIT:L576P,[Variant]
2855,"Nilotinib,Imatinib,Sorafenib",[Drug]
2856,KRAS:G12/G13,[Variant]
2857,"Gefitinib,Erlotinib",[Drug]
2858,"Chemotherapy,Cetuximab",[Drug]
2859,Neuroblastoma,[Disease]
2860,Alectinib,[Drug]
2861,ALK:R1275Q,[Variant]
2862,TAE684,[Drug]
2863,Trametinib,[Drug]
2864,Dasatinib,[Drug]
2865,PDGFRA:D842I,[Variant]
2866,Crenolanib,[Drug]
2867,PDGFRA:D842Y,[Variant]
2868,PDGFRA:I843DEL,[Variant]
2869,PDGFRA:D842_I843delinsVM,[Variant]
2870,FLT3,[Gene]
2871,FLT3:ITD,[Variant]
2872,KIT:EXON 11 MUTATION,[Variant]
2873,NRAS:G12,[Variant]
2874,KIT:EXON 14 MUTATION,[Variant]
2875,BRAF:V600E and V600M,[Variant]
2876,Dabrafenib,[Drug]
2877,RET,[Gene]
2878,RET:M918T,[Variant]
2879,Thyroid Gland Medullary Carcinoma,[Disease]
2880,RET:C634W,[Variant]
2881,Motesanib,[Drug]
2882,JAK2 Inhibitor AZD1480,[Drug]
2883,BRAF:V600E,[Variant]
2884,Thyroid Gland Cancer,[Disease]
2885,Thyroid Gland Papillary Carcinoma,[Disease]
2886,PIK3CA,[Gene]
2887,PIK3CA:E542K,[Variant]
2888,Regorafenib,[Drug]
2889,"MEK Inhibitor PD0325901,Trametinib",[Drug]
2890,KRAS:EXON 2 MUTATION,[Variant]
2891,Panitumumab,[Drug]
2892,"Panitumumab,Sorafenib",[Drug]
2893,BRAF:V600E and AMPLIFICATION,[Variant]
2894,"Dabrafenib,Trametinib",[Drug]
2895,BRAF:V600D,[Variant]
2896,"Pictilisib Bismesylate,PLX4720",[Drug]
2897,"PLX4720,Nutlin-3",[Drug]
2898,"Capecitabine,Bevacizumab,Vemurafenib",[Drug]
2899,NPM1,[Gene]
2900,NPM1:EXON 12 MUTATION,[Variant]
2901,NPM1:W288FS,[Variant]
2902,CEBPA,[Gene]
2903,CEBPA:MUTATION,[Variant]
2904,Tretinoin,[Drug]
2905,PIK3CA:EXON 10 MUTATION,[Variant]
2906,Cetuximab,[Drug]
2907,SU5614,[Drug]
2908,KRAS:G12V,[Variant]
2909,PIK3CA:EXON 21 MUTATION,[Variant]
2910,WT1,[Gene]
2911,WT1:EXON 7 MUTATION,[Variant]
2912,"Cytarabine,Daunorubicin",[Drug]
2913,ALK:EML4-ALK L1196M,[Variant]
2914,FGFR3,[Gene]
2915,FGFR3:FGFR3-BAIAP2L1,[Variant]
2916,Bladder Carcinoma,[Disease]
2917,PD173074,[Drug]
2918,KRAS:G13D,[Variant]
2919,Valproic Acid,[Drug]
2920,"Tretinoin,NSC348884",[Drug]
2921,"Anti-CD33,Anti-CD123",[Drug]
2922,Anti-CD33,[Drug]
2923,NSC348884,[Drug]
2924,Induction Therapy,[Drug]
2925,TSC1,[Gene]
2926,TSC1:FRAMESHIFT TRUNCATION,[Variant]
2927,Sirolimus,[Drug]
2928,TSC1:LOSS-OF-FUNCTION,[Variant]
2929,Everolimus,[Drug]
2930,FLT3:MUTATION,[Variant]
2931,IDH1,[Gene]
2932,IDH1:R132,[Variant]
2933,WT1:EXON 9 MUTATION,[Variant]
2934,FLT3:TKD MUTATION,[Variant]
2935,MGMT,[Gene]
2936,MGMT:PROMOTER METHYLATION,[Variant]
2937,Glioblastoma,[Disease]
2938,DNMT3A:MUTATION,[Variant]
2939,BRCA1,[Gene]
2940,BRCA1:LOSS-OF-FUNCTION,[Variant]
2941,Ovarian Cancer,[Disease]
2942,Olaparib,[Drug]
2943,BRCA2,[Gene]
2944,BRCA2:LOSS-OF-FUNCTION,[Variant]
2945,ABL1,[Gene]
2946,ABL1:BCR-ABL,[Variant]
2947,U2AF1,[Gene]
2948,U2AF1:Q157P/R,[Variant]
2949,U2AF1:S34Y/F,[Variant]
2950,CCND2,[Gene]
2951,CCND2:PROMOTER DEMETHYLATION,[Variant]
2952,Stomach Cancer,[Disease]
2953,CCND1,[Gene]
2954,CCND1:OVEREXPRESSION,[Variant]
2955,Breast Cancer,[Disease]
2956,IDH1:R132C,[Variant]
2957,KRAS:G12C,[Variant]
2958,Lung Cancer,[Disease]
2959,KRAS:G12D,[Variant]
2960,EGFR,[Gene]
2961,EGFR:L858R,[Variant]
2962,AKT1,[Gene]
2963,AKT1:E17K,[Variant]
2964,Akt Inhibitor MK2206,[Drug]
2965,ABL1:BCR-ABL E255K,[Variant]
2966,ABL1:BCR-ABL T315I,[Variant]
2967,ALK:EML4-ALK C1156Y,[Variant]
2968,EGFR:T790M,[Variant]
2969,Erlotinib,[Drug]
2970,Gefitinib,[Drug]
2971,Dacomitinib,[Drug]
2972,ERBB2,[Gene]
2973,ERBB2:L755S,[Variant]
2974,Lapatinib,[Drug]
2975,ESR1,[Gene]
2976,ESR1:L536Q,[Variant]
2977,Hormone Therapy,[Drug]
2978,ESR1:D538G,[Variant]
2979,ESR1:Y537C,[Variant]
2980,ESR1:Y537N,[Variant]
2981,ESR1:Y537S,[Variant]
2982,KIT:V654A,[Variant]
2983,KRAS:G12A,[Variant]
2984,Lung Adenocarcinoma,[Disease]
2985,PIK3CA:H1047R,[Variant]
2986,"Panitumumab,Cetuximab",[Drug]
2987,"Dasatinib,Nilotinib",[Drug]
2988,ALK:EML4-ALK,[Variant]
2989,CCND3,[Gene]
2990,CCND3:LOSS,[Variant]
2991,T-cell Lymphoblastic Leukemia/lymphoma,[Disease]
2992,Palbociclib,[Drug]
2993,CDK4,[Gene]
2994,CDK4:EXPRESSION,[Variant]
2995,Estrogen-receptor Positive Breast Cancer,[Disease]
2996,Alpelisib,[Drug]
2997,DDR2,[Gene]
2998,DDR2:G253C,[Variant]
2999,DDR2:G505S,[Variant]
3000,DDR2:G774V,[Variant]
3001,DDR2:I638F,[Variant]
3002,DDR2:L239R,[Variant]
3003,DDR2:L63V,[Variant]
3004,DDR2:S768R,[Variant]
3005,"Dasatinib,Erlotinib",[Drug]
3006,EGFR:EXON 19 DELETION,[Variant]
3007,EGFR:G719S,[Variant]
3008,"Pemetrexed,Erlotinib",[Drug]
3009,Staurosporine,[Drug]
3010,ERBB2:D769H,[Variant]
3011,"Lapatinib,Neratinib",[Drug]
3012,ERBB2:D769Y,[Variant]
3013,Neratinib,[Drug]
3014,ERBB2:L755_T759del,[Variant]
3015,ERBB2:G309A,[Variant]
3016,ERBB2:L755W,[Variant]
3017,ERBB2:P780INS,[Variant]
3018,ERBB2:R678Q,[Variant]
3019,ERBB2:R896C,[Variant]
3020,ERBB2:V777L,[Variant]
3021,ERBB2:V842I,[Variant]
3022,"Tamoxifen,Fulvestrant",[Drug]
3023,"Fulvestrant,Tamoxifen",[Drug]
3024,FGFR2,[Gene]
3025,FGFR2:FGFR2-MGEA5,[Variant]
3026,Cholangiocarcinoma,[Disease]
3027,Ponatinib,[Drug]
3028,FGFR2:FGFR2-TACC3,[Variant]
3029,"Pazopanib,Ponatinib",[Drug]
3030,Lestaurtinib,[Drug]
3031,Tyrphostin AG 1296,[Drug]
3032,GATA2,[Gene]
3033,GATA2:EXPRESSION,[Variant]
3034,"Bortezomib,Fasudil",[Drug]
3035,KIT:INTERNAL DUPLICATION,[Variant]
3036,Malignant Anus Melanoma,[Disease]
3037,"Dasatinib,Nilotinib,Imatinib",[Drug]
3038,Sunitinib,[Drug]
3039,"Dactolisib,Selumetinib",[Drug]
3040,Carmustine,[Drug]
3041,O6-Benzylguanine,[Drug]
3042,PI3K-alpha Inhibitor MEN1611,[Drug]
3043,PML,[Gene]
3044,PML:PML-RARA,[Variant]
3045,Acute Promyelocytic Leukemia,[Disease]
3046,PTEN,[Gene]
3047,PTEN:R233*,[Variant]
3048,MTOR Inhibitor,[Drug]
3049,TP53,[Gene]
3050,TP53:R175H,[Variant]
3051,Doxorubicin,[Drug]
3052,Invasive Bladder Transitional Cell Carcinoma,[Disease]
3053,IDH2,[Gene]
3054,IDH2:R140,[Variant]
3055,IDH2:MUTATION,[Variant]
3056,Myelodysplastic Syndrome,[Disease]
3057,IDH2:R172K,[Variant]
3058,CCND1:EXPRESSION,[Variant]
3059,Astrocytoma,[Disease]
3060,SF3B1,[Gene]
3061,SF3B1:MUTATION,[Variant]
3062,CCND1:AMPLIFICATION,[Variant]
3063,Head And Neck Squamous Cell Carcinoma,[Disease]
3064,Mantle Cell Lymphoma,[Disease]
3065,CCND2:OVEREXPRESSION,[Variant]
3066,CCNE1,[Gene]
3067,CCNE1:OVEREXPRESSION,[Variant]
3068,Gastric Adenosquamous Carcinoma,[Disease]
3069,CDKN2A,[Gene]
3070,CDKN2A:PROMOTER HYPERMETHYLATION,[Variant]
3071,Multiple Myeloma,[Disease]
3072,NOTCH1,[Gene]
3073,NOTCH1:D1642H,[Variant]
3074,NOTCH1:R2327W,[Variant]
3075,NOTCH1:S2275FS,[Variant]
3076,NOTCH1:V2444FS,[Variant]
3077,PIK3CA:E545K,[Variant]
3078,TP53:R248Q,[Variant]
3079,TP53:R248W,[Variant]
3080,TP53:R249,[Variant]
3081,TP53:R273C,[Variant]
3082,TP53:R273H,[Variant]
3083,CSF1R,[Gene]
3084,CSF1R:MEF2D-CSF1R,[Variant]
3085,Acute Lymphoblastic Leukemia,[Disease]
3086,"GW-2580,Imatinib",[Drug]
3087,PRKACA,[Gene]
3088,PRKACA:DNAJB1-PRKACA,[Variant]
3089,Fibrolamellar Carcinoma,[Disease]
3090,BCL2,[Gene]
3091,BCL2:IGH-BCL2,[Variant]
3092,Diffuse Large B-cell Lymphoma,[Disease]
3093,FOXP1,[Gene]
3094,FOXP1:AMPLIFICATION,[Variant]
3095,REL,[Gene]
3096,REL:AMPLIFICATION,[Variant]
3097,RUNX1,[Gene]
3098,RUNX1:MUTATION,[Variant]
3099,Cytarabine,[Drug]
3100,IGF2,[Gene]
3101,IGF2:OVEREXPRESSION,[Variant]
3102,Prostate Cancer,[Disease]
3103,Linsitinib,[Drug]
3104,"Linsitinib,Cabazitaxel,Docetaxel",[Drug]
3105,TET2,[Gene]
3106,TET2:MUTATION,[Variant]
3107,AURKA,[Gene]
3108,AURKA:EXPRESSION,[Variant]
3109,Ovarian Carcinoma,[Disease]
3110,VHL,[Gene]
3111,VHL:MUTATION,[Variant]
3112,Clear Cell Renal Cell Carcinoma,[Disease]
3113,PBRM1,[Gene]
3114,PBRM1:MUTATION,[Variant]
3115,BCL2:EXPRESSION,[Variant]
3116,EZH2,[Gene]
3117,EZH2:MUTATION,[Variant]
3118,VHL:LOSS-OF-FUNCTION,[Variant]
3119,FLI1,[Gene]
3120,FLI1:EWSR1-FLI1 Type 1,[Variant]
3121,Ewing Sarcoma,[Disease]
3122,EZH2:Y646,[Variant]
3123,Follicular Lymphoma,[Disease]
3124,KMT2D,[Gene]
3125,KMT2D:LOSS-OF-FUNCTION,[Variant]
3126,BTK,[Gene]
3127,BTK:C481S,[Variant]
3128,Chronic Lymphocytic Leukemia,[Disease]
3129,Ibrutinib,[Drug]
3130,AKT1:Q79K,[Variant]
3131,ALK:EML4-ALK and AMPLIFICATION,[Variant]
3132,ALK:ALK FUSION G1202R,[Variant]
3133,ALK:EML4-ALK S1206Y,[Variant]
3134,ALK:EML4-ALK T1151INST,[Variant]
3135,APC,[Gene]
3136,APC:MUTATION,[Variant]
3137,Colon Carcinoma,[Disease]
3138,JW55,[Drug]
3139,G007-LK,[Drug]
3140,AR,[Gene]
3141,AR:F877L,[Variant]
3142,"Apalutamide,Enzalutamide",[Drug]
3143,AR:W742,[Variant]
3144,Prostate Carcinoma,[Disease]
3145,Bicalutamide,[Drug]
3146,ASXL1,[Gene]
3147,ASXL1:MUTATION,[Variant]
3148,ATM,[Gene]
3149,ATM:MUTATION,[Variant]
3150,ATM:UNDEREXPRESSION,[Variant]
3151,Cancer,[Disease]
3152,"NU7441,KU-0060648",[Drug]
3153,Hematologic Cancer,[Disease]
3154,AURKA:AMPLIFICATION,[Variant]
3155,Esophagus Adenocarcinoma,[Disease]
3156,"Cisplatin,Alisertib",[Drug]
3157,AURKA:OVEREXPRESSION,[Variant]
3158,Cervical Adenocarcinoma,[Disease]
3159,Paclitaxel,[Drug]
3160,BAP1,[Gene]
3161,BAP1:EXPRESSION,[Variant]
3162,Uveal Melanoma,[Disease]
3163,BAP1:MUTATION,[Variant]
